



Vaccines and Global Health: The Week in Review
12 February 2022 :: Issue 644
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

Milestones - Perspectives

.....
.....

ACT-Accelerator calls for fair share-based financing of US\$ 23 billion to end pandemic as global emergency in 2022

- World leaders launch campaign to meet the US\$ 16 billion ACT-Accelerator funding gap and US\$ 6.8 billion in-country delivery costs to take vital steps towards ending the pandemic as a global emergency in 2022.
- The ACT-Accelerator initiative works to overcome vast global inequities by providing low- and middle-income countries with access to COVID-19 tests, treatments, vaccines and personal protective equipment.
- **The ACT-Accelerator agencies urgently need new funding to scale up their work to develop and deliver the COVID-19 countermeasures** essential to address the threat of Omicron and prevent even more dangerous variants from emerging.
- A diverse group of governments have agreed on a new financing framework developed in support of the ACT-Accelerator, which makes 'fair share' requests of richer countries to contribute to the global fight against COVID-19.

GENEVA, February 9, 2022 - World leaders will today launch a call to end the pandemic as a global emergency in 2022 by funding the Access to COVID-19 Tools (ACT) Accelerator, a partnership of leading agencies that is providing low and middle-income countries with tests, treatments, vaccines, and personal protective equipment.

With a significant proportion of the global population still unable to get vaccinated, tested or treated, US\$ 16 billion in grant funding is urgently required from governments to fund the work of the ACT-Accelerator agencies. This investment will allow them to procure essential tools to fight COVID-19 and provide them to low- and middle-income countries.

The ACT-Accelerator is calling for the support of higher income countries, at a time when vast global disparities in access to COVID-19 tools persist. Over 4.7 billion COVID-19 tests have been administered globally since the beginning of the pandemic. However, only about 22 million tests have been administered in low-income countries, comprising only 0.4% of the global total. Only 10% of people in low-income countries have received at least one vaccine dose. **This massive inequity not only costs lives, it also hurts economies and risks the emergence of new, more dangerous variants that could rob current tools of their effectiveness and set even highly-vaccinated populations back many months...**

.....

Calling Vaccine Inequity 'Biggest Moral Failure of Our Times', Secretary-General Says Focus Must Be on Fairness, in COVID-19 Tools Accelerator Launch Remarks

9 February 2022

SG/SM/21137

Following are UN Secretary-General António Guterres' remarks to the Access to COVID-19 Tools Accelerator (ACT-Accelerator) campaign launch, held virtually, today:

I am pleased to join all of you to launch this resource mobilization campaign for the ACT-Accelerator. I thank you for putting the focus on fairness. If we want to ensure vaccinations for everyone to end this pandemic, we must first inject fairness into the system.

We are entering the third year of the pandemic — and the world is still far from meeting crucial targets: to vaccinate the globe; to increase testing; to make life-saving effective treatments available for all who need it; to protect our front-line health-care workers with quality personal protection equipment.

Vaccine inequity is the biggest moral failure of our times — and people and countries are paying the price. The good news is that recent progress shows how we can deliver when we have the resources and come together.

Vaccine supply and roll-out is ramping up exponentially and we are making up for lost time in many countries. The end of this pandemic can be within our sights — this year. We can get the economic recovery back on track and rescue the Sustainable Development Goals. But, we need to act now.

Vaccines, tests and effective treatments are available. Yet, many low- and middle-income countries are still not getting enough of these pandemic-ending tools to protect their families and communities — and our world. Until and unless we can ensure access to these tools, the pandemic will not go away, and the sense of insecurity of people will only deepen. We have the systems to accelerate the roll-out of these essential tools.

The United Nations family has decades of experience working with countries and communities in crisis. United Nations agencies — led by the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) — have the know-how to help Governments turn vaccines into vaccination, tests into testing, and treatments into effective clinical care for patients.

But, we cannot access the tools — without first accessing the resources to support countries to achieve global vaccination, testing and treatment targets. The ACT-Accelerator provides a costed, coordinated and credible path out of the COVID-19 pandemic for everyone, everywhere. This needs to be financed by fair share contributions from countries.

Above all, we need urgent investment in timely vaccine delivery and increasing testing. This is a matter of fairness — but also it is a matter of justice — and it is a matter of plain old common sense.

We can end the pandemic this year. We have the pathway to get there. But, we can only get there together. It is all up to us — and it all comes down to fairness. Thank you and I wish this meeting the best possible success to the benefit of humankind.

.....
.....

[Remarks by UNICEF Executive Director Catherine M. Russell at the opening of the UNICEF Executive Board](#)

02/08/2022

As prepared for delivery

...I want to begin by thanking Secretary General Guterres and all the members of the Executive Board for the opportunity to lead this extraordinary organization.

Children are the world's most precious resource. There is no greater cause than championing their rights and wellbeing. I am committed to this cause with all my heart, and I am proud to join the UNICEF family.

I would like to acknowledge and thank my predecessor, Henrietta Fore, for her leadership of UNICEF over the last four years -- especially for skillfully guiding UNICEF's global response to the COVID-pandemic, and for engaging every sector to support the world's most vulnerable children.

For 75 years, UNICEF has stood for a powerful truth: Every child has the right to grow up healthy and strong. To be nurtured and protected. To be educated and prepared to contribute to their societies. And for 75 years, UNICEF and our partners have worked to help children realize those rights, wherever they are...

...All these threats to children are harmful enough on their own. COVID-19 has exponentially increased their impact.

From the very first weeks and months of the pandemic, **UNICEF has been responding to the direct risks COVID-19 posed to children and families.** Through COVAX, we are helping lead the largest vaccine procurement and supply operation in history, using our unique expertise as the world's biggest vaccine buyer and our on-the-ground delivery capacity.

We continue to focus our efforts on expanding vaccine access for communities in low- and middle-income countries -- and reaching those hardest to reach. It is unconscionable that in the world's poorest countries, fewer than 10 percent of people have received at least one dose of vaccine. UNICEF is working with our partners to change this, including by procuring and delivering COVID-19 vaccines to African Union Member States, on behalf of the African Vaccine Acquisition Trust.

We still have a long way to go to turn vaccines into vaccinations -- and to reach every arm. To achieve vaccine equity, we need more partners to join us, and we must have a fully coordinated global effort. That is why we are requesting your endorsement for the establishment of a new senior position to support COVID-19 vaccine country-readiness and delivery. This role will coordinate interagency efforts to forecast vaccine needs, as well as provide financial and technical assistance to overcome bottlenecks.

We will continue working to make progress on vaccine distribution and access. But the last two years have shown us that it is not enough to mitigate the spread of COVID-19. We also need to mitigate the pandemic's impact on children.

The numbers are staggering. **We estimate that 100 million more children are now living in poverty because of the pandemic** -- a 10 per cent increase since 2019. Increasing poverty could push an additional 9 million children into child labor by the end of this year. More than 616 million children are still affected by full or partial school closures, something I will say more about in a moment.

In 2020 alone, an additional 23 million children didn't receive essential vaccinations that protect their lives and their healthy development.

An additional 9 million children are at risk of wasting, the deadliest form of malnutrition -- many of them caught in humanitarian crises without access to treatment. UNICEF estimates that an additional 10 million girls are at risk for child marriage, and there is mounting evidence of increases in gender-based violence and sexual abuse. And children's mental health has been severely impacted during the pandemic, in high-, middle-, and low-income countries alike.

These figures represent the lives and futures of millions of children -- and the future of their societies. The economic impact of pandemic-caused school closures alone could cause a \$17 trillion loss in lifetime earnings for this entire generation of schoolchildren.

The world cannot continue to overlook children in the COVID-19 response and recovery. Children should not have to bear the cost of this pandemic for the rest of their lives.

UNICEF is calling on governments to put children at the center of global, national, and local pandemic response and recovery plans...

.....
.....

Featured Journal Content

Editor's Note:

We feature three journal articles of particular interest below. The first two were selected for their pandemic focus and their timing as we seem to be slipping into a dangerous and evidence-devoid "post-pandemic mindset [as least in the Global North]. The third was selected based on the continuing and apparently intractable "zero-dose" children challenge and the article's analysis of how this plays out across ethnic groups.

medRxiv

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

[Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era](#)

Alexandra Savinkina, Alyssa Bilinski, Meagan C Fitzpatrick, A David Paltiel, Zain Rizvi, Joshua A Salomon, Thomas Thornhill, Gregg S. Gonsalves

doi: <https://doi.org/10.1101/2022.02.08.22270465>

Posted February 09, 2022

Abstract

Background:

While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries has received a full primary vaccine series, compared to over 70% of the population of high-income nations.

Methods:

We used economic and epidemiologic models, parameterized with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programs in low and lower-middle income countries (LIC/LMIC) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2. Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up, and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs.

Findings:

:: Global scale up of vaccination to provide two doses of mRNA vaccine to everyone in LIC/LMIC would cost \$35.5 billion and avert 1.3 million deaths from COVID-19, at a cost of \$26,900 per death averted.

:: Scaling up vaccination to provide three doses of mRNA vaccine to everyone in LIC/LMIC would cost \$61.2 billion and avert 1.5 million deaths from COVID-19 at a cost of \$40,800 per death averted.

:: Lower estimated infection fatality ratios, higher cost-per-dose, and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis.

Interpretation:

Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life (VSL). Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.

Table 3. Model results for total cost of global vaccination of low and lower-middle income countries (in billions US\$), total deaths averted (in millions), and cost per death averted (US\$). The model assumes an IFR for pre-Omicron COVID: 5/1000, IFR for Omicron: 1/1,000, cost per dose \$7, natural immunity protection against mortality 80%, vaccine effectiveness against mortality with two doses: 80%, vaccine effectiveness against mortality with three doses: 90%.

	Two Dose Scenario	Three Dose Scenario
Total cost (US\$, billion)	\$35.52	\$61.21
Total vaccine doses needed (billion)	5.07	8.74
Total deaths averted (million)		
Using reported COVID-19 deaths to calculate prior infection	2.14	2.40
Using excess mortality estimates to calculate prior infection (and 95% CI) ₁	1.32 (0.87-1.97)	1.50 (1.02-2.22)
Cost per death averted (US\$)		
Using reported COVID-19 deaths to calculate prior infection	\$16,700	\$25,500
Using excess mortality estimates to calculate prior infection (and 95% CI) ₁	\$26,900 (\$18,000-\$40,000)	\$40,800 (\$27,600-\$59,900)

1. 95% CI from excess mortality calculations from The Economist¹¹

.....

The Lancet

Articles| Online First

[Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021](#)

[COVID-19 National Preparedness Collaborators](#)

Open Access Published: February 01, 2022

DOI:[https://doi.org/10.1016/S0140-6736\(22\)00172-6](https://doi.org/10.1016/S0140-6736(22)00172-6)

Summary

Background

National rates of COVID-19 infection and fatality have varied dramatically since the onset of the pandemic. Understanding the conditions associated with this cross-country variation is essential to guiding investment in more effective preparedness and response for future pandemics.

Methods

Daily SARS-CoV-2 infections and COVID-19 deaths for 177 countries and territories and 181 subnational locations were extracted from the Institute for Health Metrics and Evaluation's modelling database. Cumulative infection rate and infection-fatality ratio (IFR) were estimated and standardised for environmental, demographic, biological, and economic factors. For infections, we included factors associated with environmental seasonality (measured as the relative risk of pneumonia), population density, gross domestic product (GDP) per capita, proportion of the population living below 100 m, and a proxy for previous exposure to other betacoronaviruses. For IFR, factors were age distribution of the population, mean body-mass index (BMI), exposure to air pollution, smoking rates, the proxy for previous exposure to other betacoronaviruses, population density, age-standardised prevalence of chronic obstructive pulmonary disease and cancer, and GDP per capita. These were standardised using indirect age standardisation and multivariate linear models. Standardised national cumulative infection rates and IFRs were tested for associations with 12 pandemic preparedness indices, seven health-care capacity indicators, and ten other demographic, social, and political conditions using linear regression. To investigate pathways by which important factors might affect infections with SARS-CoV-2, we also assessed the relationship between interpersonal and governmental trust and corruption and changes in mobility patterns and COVID-19 vaccination rates.

Findings

The factors that explained the most variation in cumulative rates of SARS-CoV-2 infection between Jan 1, 2020, and Sept 30, 2021, included the proportion of the population living below 100 m (5·4% [4·0–7·9] of variation), GDP per capita (4·2% [1·8–6·6] of variation), and the proportion of infections attributable to seasonality (2·1% [95% uncertainty interval 1·7–2·7] of variation). Most cross-country variation in cumulative infection rates could not be explained. The factors that explained the most variation in COVID-19 IFR over the same period were the age profile of the country (46·7% [18·4–67·6] of variation), GDP per capita (3·1% [0·3–8·6] of variation), and national mean BMI (1·1% [0·2–2·6] of variation). 44·4% (29·2–61·7) of cross-national variation in IFR could not be explained.

Pandemic-preparedness indices, which aim to measure health security capacity, were not meaningfully associated with standardised infection rates or IFRs. Measures of trust in the government and interpersonal trust, as well as less government corruption, had larger, statistically significant associations with lower standardised infection rates.

High levels of government and interpersonal trust, as well as less government corruption, were also associated with higher COVID-19 vaccine coverage among middle-income and high-income countries where vaccine availability was more widespread, and lower corruption was associated with greater reductions in mobility.

If these modelled associations were to be causal, an increase in trust of governments such that all countries had societies that attained at least the amount of trust in government or interpersonal trust measured in Denmark, which is in the 75th percentile across these spectrums, might have reduced global infections by 12·9% (5·7–17·8) for government trust and 40·3% (24·3–51·4) for interpersonal trust. Similarly, if all countries had a national

BMI equal to or less than that of the 25th percentile, our analysis suggests global standardised IFR would be reduced by 11·1%.

Interpretation

Efforts to improve pandemic preparedness and response for the next pandemic might benefit from greater investment in risk communication and community engagement strategies to boost the confidence that individuals have in public health guidance. Our results suggest that increasing health promotion for key modifiable risks is associated with a reduction of fatalities in such a scenario.

Funding

Bill & Melinda Gates Foundation, J Stanton, T Gillespie, J and E Nordstrom, and Bloomberg Philanthropies.

Research in context

Evidence before this study

Responsive policies such as physical distancing and mask mandates were important in shaping outcomes during the COVID-19 pandemic. Yet, the conditions associated with cross-country variation in infection and fatality rates during the COVID-19 pandemic are not well understood. In the aftermath of the 2013–16 Ebola epidemic in west Africa, WHO launched a voluntary Joint External Evaluation (JEE) process to track adoption of core capacities required under the 2005 International Health Regulations and to assess national capacity to prevent, detect, and respond to disease with potential for pandemic spread. WHO's April 2021 interim assessment did not find JEE scores from the 100 countries that had conducted voluntary assessments to be correlated with COVID-19 outcomes, although such metrics were designed as benchmarking exercises for National Action Plans rather than cross-country comparators. Preliminary analysis of COVID-19 outcomes in relation to other health-system capacity indices, such as the Global Health Security Index and the index of effective coverage of universal health coverage produced by the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) have also been found not to be predictive of COVID-19 outcomes. Other exploratory research on COVID-19 outcomes has had a regional focus or has focused on a small number of country experiences.

Added value of this study

We analysed measures of pandemic preparedness. 12 indicators of preparedness and response and seven indicators of health-system capacity were considered, in addition to ten other demographic, social, and political conditions that previous research suggests might be relevant. Associations with both incidence and mortality from SARS-CoV-2 infections were investigated. We controlled for demographic, biological, economic, and environmental variables associated with COVID-19 outcomes, including population age structure and environmental seasonality, population density, national income, and population health risks, to identify contextual factors subject to policy control. **This research considerably expands on the scope of previous research by investigating correlates of pandemic preparedness and mitigation** in 177 countries between Jan 1, 2020, and Sept 30, 2021, and includes inputs that have been adjusted for problems associated with under-reporting of COVID-19 outcomes. This expanded scope was possible because of inputs from COVID-19 research produced by the Institute for Health Metrics and Evaluation and mortality and population estimates generated by GBD.

Implications of all the available evidence

The existing metrics for health-system capacity and national pandemic preparedness and response have been poor predictors of pandemic outcomes, suggesting other areas might merit greater weight

in future preparedness efforts. Not all of the correlates that account for some variation in infections per capita and infection-to-fatality ratios, such as age structure, altitude at which a population lives, and environmental seasonality, are easy for policy makers to control. Yet, other factors are within the policy realm, including preventive health measures focused on population health fundamentals: encouraging healthy bodyweight and reducing smoking might be helpful in averting morbidity and mortality in future pandemic scenarios. **Moreover, the level of trust is something that a government can prepare for and earn in a crisis, and our analysis suggests doing so may be crucial to mount a more effective response to future pandemic threats. Large unexplained variation in differences in SARS-CoV-2 infections across countries speaks to the importance of further research in this area.**

.....

medRxiv

This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Ethnic disparities in immunisation: analyses of zero-dose prevalence in 64 low- and middle-income countries

Bianca Oliveira Cata-Preta, Thiago Melo Santos, Andrea Wendt, Daniel R Hogan, Tewodaj Mengistu, Aluisio Jardim Dornellas Barros, Cesar Gomes Victora

medRxiv 2022.02.09.22270671; doi: <https://doi.org/10.1101/2022.02.09.22270671>

Posted February 10, 2022.

Abstract

Background The Sustainable Development Goals (SDGs) recommend stratification of health indicators by ethnic group, yet there are few studies that have assessed if there are ethnic disparities in childhood immunisation in low and middle income countries (LMICs).

Methods We identified 64 LMICs with standardized national surveys carried out since 2010, which provided information on ethnicity or a proxy variable and on vaccine coverage; 339 ethnic groups across the 64 countries were identified after excluding those with fewer than 50 children in the sample and countries with a single ethnic group. Lack of vaccination with diphtheria-pertussis-tetanus (DPT) vaccine, a proxy for no access to routine vaccination or zero-dose status, was the outcome of interest. Differences among ethnic groups were assessed using a chi-squared test for heterogeneity. Additional analyses controlled for household wealth, maternal education and urban-rural residence.

Findings The median gap between the highest and lowest zero-dose prevalence ethnic groups in all countries was equal to 10 percentage points (interquartile range 4-22; range 1 to 84) and the median ratio was 3.3 (interquartile range 1.8-6.7; range 1.1-30.4). In 35 of the 64 countries, there was significant heterogeneity in zero-dose prevalence among the ethnic groups. In most countries, adjustment for wealth, education and residence made little difference to the ethnic gaps, but in four countries (Angola, Benin, Nigeria, and Philippines) the high-low ethnic gap decreased by over 15 pp after adjustment. Children belonging to a majority group had 29% lower prevalence of zero-dose compared to the rest of the sample.

Interpretation **Statistically significant ethnic disparities in child immunisation were present in over half of the countries studied. Such inequalities have been seldom described in the published literature.** Regular analyses of ethnic disparities are essential for monitoring trends, targeting resources and assessing the impact of health interventions to ensure zero-dose children are not left behind in the Sustainable Development Goals era.

.....

.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 11 Feb 2022


Confirmed cases :: 404 910 528

Confirmed deaths :: 5 783 776

Vaccine doses administered: 10 095 615 243

.....

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 6 February 2022**



**See [Annex 2: Data, table, and figure notes](#)

Weekly epidemiological update on COVID-19 - 08 February 2022

Overview

Globally, during the week of 31 January to 6 February 2022, the number of new COVID-19 cases decreased by 17% as compared to the number reported during the previous week, while the number of new deaths increased by 7%. Across the six WHO regions, over 19 million new cases and just under 68 000 new deaths were reported. As of 6 February 2022, over 392 million confirmed cases and over 5.7 million deaths have been reported globally.

In this edition, we provide updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the spread and prevalence of the Omicron variant. We also provide updates on vaccine effectiveness for the Delta and Omicron variants.

.....
.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

11 February 2022

Speech

WHO Director-General's remarks at mRNA Technology Transfer Hub – 11 February 2022

[Excerpt]

...One of the most obvious lessons of the pandemic, therefore, is the urgent need to increase local production of vaccines, especially in low- and middle-income countries.

That's why, in April last year, WHO issued a call for expressions of interest for establishing a technology transfer hub for mRNA vaccines.

The turnout of applications was high but South Africa was chosen and established here in South Africa, as a partnership between WHO, Afrigen Biologics, the Biologicals and Vaccines Institute of Southern Africa, or Biovac, the South African Medical Research Council, the Africa Centres for Disease Control and Prevention, and the Medicines Patent Pool.

We very much appreciate the strong support for the hub from Belgium, Canada, the European Union, France, Germany and Norway.

And it's already producing results, with Afrigen's announcement last week that it has produced its own mRNA vaccine, based on publicly available information about the composition of an existing vaccine. And the mRNA technology is not just for COVID. It will be for malaria, TB and HIV – it will be a game changer.

We expect this vaccine to be more suited to the contexts in which it will be used, with fewer storage constraints and at a lower price.

The Medicines Patent Pool will manage the intellectual property, and where necessary issue licences to manufacturers.

Once a vaccine has been successfully developed, other manufacturers from around the world will be able to produce the vaccine for national and regional use. Many of the countries that have asked to serve as a hub will become a spoke, and there will be a network of institutions working together.

We expect clinical trials to start in the fourth quarter of this year, with approval expected in 2024. Spokes in other countries receiving the technology should be able to receive approval shortly thereafter.

I congratulate Afrigen on this achievement, and WHO looks forward to supporting you as you take this vaccine candidate into clinical trials and beyond...

9 February 2022

Speech

WHO Director-General's remarks at the ACT Accelerator Advocacy Event – 9 February 2022

7 February 2022

Speech

WHO Director-General's opening remarks at the signing ceremony for the MoU between WHO and the Commonwealth Secretariat – 7 February 2022

.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021

[Full scale view available at title link above]

[No change from 23 December 2021]

.....

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

Press Releases - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - See Russia below

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

February 9, 2022

[Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering](#)

February 8, 2022

[Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine](#)

Novavax

Press Releases

[Novavax Statement on First Administration of its COVID-19 Vaccine in Australia](#)

Feb 11, 2022

The first dose of Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) was administered today in Australia during a press briefing by The Hon Greg Hunt MP, Federal Minister for Health and Aged Care. Nuvaxovid is the first protein-based COVID-19 vaccine to receive approval for provisional registration by the Therapeutic Goods Administration (TGA)...

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Feb 10, 2022

- *PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population*
- *Trial demonstrated 82% clinical efficacy against Delta variant*
- *Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied*
- *Vaccine was well-tolerated with no safety signals identified*
- *Novavax plans to supplement global regulatory filings with pediatric data in Q1 2022*

Pfizer

Recent Press Releases

02.11.2022

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their [rolling submission](#) to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, **which had been requested by FDA.**

The trial in children 6 months through 4 years of age is ongoing and data on the first two 3 µg doses in this age group are being shared with the FDA on an ongoing basis. Cases continue to accumulate according to the study protocol and more data are being generated because rates of infection and illness remain high in children of this age, especially due to the recent Omicron surge.

In December 2021, Pfizer and BioNTech [announced](#) that the ongoing clinical study would evaluate a third 3 µg dose at least two months after the second dose of the two-dose series in this age group. Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group. This is also supported by recent observations of three dose booster data in several other age groups that seems to meaningfully augment neutralizing antibody levels and real world vaccine protection for omicron compared to the two-dose regimen. The companies expect to have three-dose protection data available in early April.

The independent Data Monitoring Committee (DMC) for the study supports the continuation of the trial according to the protocol and believe that the data collected to date indicate the vaccine is well tolerated and support a potential three-dose regimen.

The extension allows the FDA time to receive updated data on the two and three-dose regimen, conduct a thorough evaluation of it and facilitate a robust, public discussion.

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases

[**Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States**](#)

February 08, 2022

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases

[**SK bioscience Begins Shipment of First Authorized Protein-Based COVID-19 Vaccine**](#)

- A vaccine platform with long-term well-understood safety and efficacy is expected to induce more participants to vaccination who are reluctant to.
- SK started supplying 2 million doses of Nuvaxovid from L-House.
- A total of 40 million doses will be distributed for domestic use in Korea.

Valneva

Press Releases - No new digest announcements identified

.....

.....

[**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 12 Feb 2022**](#)


An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

**33**vaccines **approved for use** by at least one national regulatory authority ¹**10**vaccines in WHO's **Emergency Use Listing****17.7bn**doses **secured globally****\$2-\$40**reported vaccine **price range** per dose**2.8bn**doses **COVAX** has secured from funded agreements and confirmed donations**1.16bn**doses **shipped through COVAX** to **144** countries

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Progress Towards 70% Vaccine Coverage by Mid-2022 ^{1/}




Source: IMF and WHO Staff calculations. ^{1/} Broadly, all countries that are at risk of missing the 70% target by mid-2022 are also below 40% as of early Feb 2022.



Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>




.....
.....

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 12 Feb 2022]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



.....
.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing


and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)
[See our COVID Vaccine Manufacturing research](#)
[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries



Data updated on Feb 8th 2022

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

12 Feb 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 405M total confirmed cases; 5.8M total confirmed deaths Global vaccines administered: 10.2B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 240M

Other Delivered (Number of Doses): 220M

Total Delivered (Number of Doses): 460M

Total Administered (Number of Doses): 260M

.....
.....



Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **12 Feb 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 12 Feb 2022]

:: [61.7%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [10.34 billion doses](#) have been administered globally, and [27.51 million](#) are now administered each day.

:: Only [10.6%](#) of people in low-income countries have received at least one dose.

Share of people who completed the initial COVID-19 vaccination protocol, Feb 11, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 12 February 2022, 07:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Feb 11, 2022

Share of people who completed the initial COVID-19 vaccination protocol, Feb 11, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 12 February 2022, 07:30 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Feb 11, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron

Thursday, February 10, 2022

BARDA – U.S. Department of HHS [to 12 Feb 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant

Friday, February 11, 2022

USG purchases additional Evusheld

Friday, February 11, 2022

FDA

Press Announcements

February 11, 2022 - Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant

February 11, 2022 - Coronavirus (COVID-19) Update: FDA Postpones Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age

[Editor's text bolding]

The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age. As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial. **Based on the agency's preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.**

Therefore, the FDA is postponing the Vaccines and Related Biological Products Advisory Committee meeting originally scheduled for Feb. 15. This will give the agency time to consider the additional data, allowing for a transparent public discussion as part of our usual scientific and regulatory processes for COVID-19 vaccines. **We will provide an update on timing for the advisory committee meeting once we receive additional data on a third dose in this age group from the company's ongoing clinical trial and have an opportunity to complete an updated evaluation.**

Since the early days of the pandemic, **we have always followed the science** in this ever-changing situation. Given the recent omicron surge and the notable increase in hospitalizations in the youngest children to their highest levels during the pandemic so far, **we felt it was our responsibility as a public health agency to act with urgency and consider all available options, including requesting that the company provide us with initial data on two doses from its ongoing study.** The goal was to understand if two doses would provide sufficient protection to move forward with authorizing the use of the vaccine in this age group. Our approach has always been to conduct a

regulatory review that's responsive to the urgent public health needs created by the pandemic, while adhering to our rigorous standards for safety and effectiveness. Being able to begin evaluating initial data has been useful in our review of these vaccines, **but at this time, we believe additional information regarding the ongoing evaluation of a third dose should be considered.**

The agency will ensure the data support effectiveness and safety before authorizing a COVID-19 vaccine for use in our youngest children. In the meantime, the best way to protect children, including when they are at school or daycare, is to practice social distancing and masking in accordance with public health recommendations, and for their family members and caregivers to get vaccinated or receive a booster dose when eligible.

Editor's Note:

We repeat below the announcement from last week's edition for reference. See also the Pfizer-Biontech announcement:

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age 02.11.2022

February 1, 2022 - Coronavirus (COVID-19) Update: FDA Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration is announcing a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 15 to **discuss the request for emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age.**

"Having a safe and effective vaccine available for children in this age group is a priority for the agency and we're committed to a timely review of the data, which the agency asked Pfizer to submit in light of the recent Omicron surge. Furthermore, children are not small adults. Because they're still growing and developing, it's critical that these vaccines are evaluated in well-designed and well-conducted clinical trials," said Acting FDA Commissioner Janet Woodcock, M.D. "In the meantime, the best way to protect children, including when they are at school or daycare, is to practice social distancing and masking in accordance with public health recommendations, and for their family members and caretakers to get vaccinated or receive a booster dose when eligible."...

"The need for a safe and effective vaccine for our youngest children is significant, particularly given the rapid spread of the omicron variant, the notable rise in the number of hospitalizations in young children with severe disease, and the possibility that future variants could cause severe disease in those who are unvaccinated," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "As we have done for other COVID-19 vaccine authorizations, this meeting will help ensure that the public has a clear understanding of the data and information the FDA will evaluate as it considers whether to authorize the vaccine. We are committed to a transparent process, which will include input from our external advisors."

The FDA intends to make background material available to the public, including the meeting agenda and committee roster, no later than two business days before the meeting...

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

THIS MEETING IS POSTPONED. Vaccines and Related Biological Products Advisory Committee February 15, 2022 Meeting Announcement - 02/15/2022

Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement - 03/03/2022

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

Press Briefing by White House COVID-19 Response Team and Public Health Officials

February 09, 2022 *Press Briefings*

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

Press Statement

COVID-19 Global Action Meeting

Antony J. Blinken February 11, 2022

...My counterparts and leaders from regional and international organizations will discuss the leadership roles and actions we will take under the COVID-19 Global Action Plan (GAP), which builds on President Biden's Global COVID-19 Summit themes of vaccinating the world, saving lives now, and building better health security. Specifically, we are asking countries to step up with us to: (1) Get Shots in Arms; (2) Bolster Supply Chain Resilience; (3) Address Information Gaps; (4) Support Health Care Workers; (5) Ensure Acute Non-Vaccine Interventions; and (6) Strengthen the Global Health Security Architecture. We will coordinate responsibility for sectoral, regional, and global leadership in each line of effort, building on the momentum generated by the COVID-19 Summit and continuing regular engagement among foreign ministers to address health security.

Secretary Blinken's opening remarks will be streamed on State.gov at 08:30 EST on February 14, 2022.

Editor's Note:

We paused when reading above that U.S. is asserting that its role might properly be to "...coordinate responsibility for sectoral, regional, and global leadership in each line of effort..." as inventoried.

.....

.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU (new)

Last updated: 09/02/2022

News: EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents (new)

CHMP, Last updated: 08/02/2022

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates [Selected]

News

[COVID-19 vaccines for adolescents offer a very high level of protection against infection, symptomatic disease, and severe disease](#)


News - 8 Feb 2022

Publication

[COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose](#)

Technical report - 8 Feb 2022

.....



Accessed 12 Feb 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Speech 11 February 2022

[Speech by President von der Leyen at the One Ocean Summit](#)

President von der Leyen addressed the One Ocean Summit in Brest and presented ambitious initiatives to promote a cleaner, healthier and safer ocean.

Press release 11 February 2022

[One Ocean Summit: new steps strengthen EU leadership in protecting the Ocean](#)

The Commission is presenting today ambitious initiatives to promote a cleaner, healthier and safer ocean, as part of the EU's contribution to the One Ocean Summit hosted by France in Brest and a demonstration of EU's leading role in bringing a comprehensive response to oceans challenges.

Press release 10 February 2022

European Health Union: HERA launches first work plan with €1.3 billion for preparedness and response to health emergencies in 2022

The new European Health Emergency Preparedness and Response Authority (HERA) today presents its first annual work plan, which will have a budget of €1.3 billion in 2022 to prevent, prepare for and rapidly respond to cross-border health emergencies.

Statement 9 February 2022

Statement by President von der Leyen at the Institut Pasteur of Dakar

President von der Leyen visited the Institut Pasteur in Dakar and announced an additional contribution of €125 million to advance vaccination against COVID-19 in Africa.


Press release 9 February 2022

Protecting biodiversity: EU takes action to prevent introduction of invasive alien species that would damage European nature

The Commission is taking legal steps against 15 Member States in order to step up the prevention and management of invasive alien species.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment





Accessed 12 Feb 2022. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

The one-component Sputnik Light vaccine has been authorized in India; over 2.5 billion people live in countries that approved Sputnik Light as a standalone vaccine and a universal booster

Press release, 06.02.2022

Sputnik Light will be an important part of India's vaccination program and the fight against mutations of COVID, including Omicron.

Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people.

.....


India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare


<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
 12 February 2022, 08:00
 IST (GMT+5:30)

(↑↓ Status change since
 yesterday)



COVID-19 Vaccination
 as on : 12 February
 2022, 08:00 IST
 (GMT+5:30)



10.02.2022 **List of Countries/Regions in respect of which primary vaccination schedule completion certificate is allowed to be uploaded (in context of guidelines for international arrivals updated on 10th February 2022)**

Government of India – Press Information Bureau

Latest Press Releases

India's Cumulative COVID-19 Vaccination Coverage exceeds 172.29 Cr

:: More than 46.82 lakh Vaccine Doses administered in the last 24 hours

:: Recovery Rate currently stands at 97.37%

:: 50,407 New Cases reported in the last 24 hours

:: India's Active Caseload currently stands at 6,10,443

:: Weekly Positivity Rate is presently at 5.07%

Posted On: 12 FEB 2022 9:42AM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Over 3.02b COVID-19 vaccine doses administered on Chinese mainland

2022-02-11

More than 3.02 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Feb 10.

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 09 February 2022

:: Dr Pascal Mkanda, Director for the Polio Eradication Programme in the World Health Organization's Regional Office for Africa (AFRO), also famously known as our 'villager in polio', is this month (February 2022) entering a well-deserved retirement. Pascal's contribution over the years to polio eradication in Africa, and indeed broader immunization, is second to none. Read more about his journey to polio eradication.

:: At its fourth meeting held this week, the EMRO Regional Subcommittee on Polio Eradication and Outbreaks issued two statements, on the importance of achieving and sustaining a polio-free Eastern Mediterranean, specifically on stopping wild poliovirus transmission in Afghanistan and Pakistan and on stopping cVDPVs in Yemen.

:: "I hope one day I can tell my son the story of how polio was eradicated and how no child will ever be paralyzed by this virus again." – Dr Nida Ali a former polio worker in Pakistan shares her experience contributing to the programme. Read more...

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **Afghanistan:** one WPV1 case
- **Congo:** one cVDPV2 positive environmental sample
- **DR Congo:** one cVDPV2 case
- **Niger:** five cVDPV2 cases
- **Nigeria:** two cVDPV2 cases and 14 positive environmental samples

.....

Statement on stopping wild poliovirus transmission in Afghanistan and Pakistan

:: Statement by the Eastern Mediterranean Ministerial Regional Subcommittee on Polio Eradication and Outbreaks

:: Delivering on a promise: achieving and sustaining a polio-free Eastern Mediterranean Region

Fourth Meeting of the Regional Subcommittee on Polio Eradication and Outbreaks

[Excerpt]

...We, the Eastern Mediterranean Regional Subcommittee on Polio Eradication and Outbreaks:

DECLARE:

1. The ongoing circulation of wild poliovirus in Afghanistan and Pakistan to be a Regional Public Health Emergency; and,

COMMIT TO:

2. Enhancing engagement and support by all political, community and civil society leaders and sectors at all levels, needed to fully resolve the afore-declared Regional Public Health Emergency;

3. Supporting the coordination of activities across borders to ensure synchronized and cross-border response activities, including in Pakistan and Afghanistan.

REQUEST:

4. The international donor and development community to provide the much-needed humanitarian relief and financing to sustain and expand health services to the people of Afghanistan;

5. The sustained and strengthened commitment by all leaders at all levels in Afghanistan and Pakistan, to capitalise on the current epidemiological window of opportunity through intensified eradication efforts, including by continuing to increase access to all children in previously inaccessible areas, implementing area-specific emergency action plans in known under-performing areas and responding to the detection of any new viruses from any source (be it from an acute flaccid paralysis case or environmental sample) as an emergency;

6. All authorities in Afghanistan to facilitate resumption of house-to-house vaccination in all areas to ensure delivery of vaccine to the youngest and most vulnerable children who are not being reached by mosque-to-mosque only vaccination and who must be vaccinated to capitalize on the current opportunity across both countries...

.....

.....


Disease Outbreak News (DONs)

:: Measles – Afghanistan

10 February 2022

Measles is endemic in Afghanistan, with almost all provinces reporting suspected cases every year. Following periods of lower transmission in 2019 and 2020, and amid the humanitarian crisis in Afghanistan, weekly notifications of suspected measles cases have been increasing in all provinces since the end of July 2021, with the **highest weekly toll observed in the last four weeks in January 2022 (Figure 1). The number of cases and deaths increased by 18% and 40% respectively from week 4, 2022 (week commencing January 24) to week 5, 2022 (week commencing January 31).**

Figure 1. Weekly number of reported suspected measles cases in Afghanistan. Week 1, 2018 to week 4, 2022. Source: WHO Country Office in Afghanistan, WHO Regional Office for the Eastern Mediterranean.



.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) [Last apparent update: 17 Jan 2022]

[Crisis in Northern Ethiopia](#) [Last apparent update: 1 June 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) [Last apparent update: 17 Aug 2021]

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) [Last apparent update: 17 Aug 2021]

[Coronavirus disease \(COVID-19\) pandemic](#) [See COVID above]

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) *[Last apparent update: 24 July 2018]*

[Yemen crisis](#) *[Last apparent update: 12 February 2021]*

[Syria crisis](#) *[Last apparent update: 18 June 2021]*

[Somalia crisis](#) *[Last apparent update: 24 March 2018]*

[Nigeria crisis](#) *[Last apparent update: 1 Oct 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) *[Last apparent update: 17 Aug 2021]*

[Zika virus disease outbreak, 2015-2016](#) *[Last apparent update: 24 Jan 2020]*

[Ebola outbreak: West Africa, 2014-2016](#) *[Last apparent update: 17 Aug 2021]*

[Iraq crisis](#) *[Last apparent update: 9 Jan 2008]*

[South Sudan crisis](#) *[Last apparent update: 23 Sep 2020]*

[Avian influenza A \(H7N9\) virus outbreak](#) *[Last apparent update: 13 September 2021]*

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) *[Last apparent update: 10 Aug 2010]*

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

[Afghanistan](#)

No new updates identified.

[Northern Ethiopia](#)

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 10 February 2022](#)

HIGHLIGHTS

- Humanitarian operations in Tigray are largely reduced or suspended due to lack of fuel, cash and supplies.
- The second phase of the measles vaccination campaign in Tigray concluded reaching 595,000 children in 69 locations.

- Malnutrition rates among children and pregnant and lactating women in Tigray, Amhara and Afar remain alarmingly high, reaching 95% among screened women during the week in Tigray.
- More than one million people assisted with food in Amhara during the week under two food distribution rounds, and nearly 85,000 people assisted in Afar.
- The ongoing fighting in Afar continue to drive large-scale displacement and increased needs in the region, and to block the delivery of humanitarian supplies into Tigray.

.....

WHO & Regional Offices [to 12 Feb 2022]

<https://www.who.int/>

News [Selected]

11 February 2022

Departmental news

WHO prequalifies first monoclonal antibody - tocilizumab – to treat COVID-19

Aiming to increase access to recommended treatments for COVID-19, WHO today added tocilizumab, a monoclonal antibody, to its list of prequalified treatments for COVID-19. To date, six COVID-19 treatments have been prequalified by WHO, including the three presentations (three vials, each with a different quantity) of the product prequalified today.

The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification, thereby increasing the number of quality-assured products and creating competition leading to potentially lower prices. The prequalification of these products will also facilitate low- and middle-income countries' authorization of them as COVID treatments.

Tocilizumab is a monoclonal antibody that inhibits the Interleukin-6 (IL-6) receptor. Interleukin-6 induces an inflammatory response and is found in high levels in patients critically ill with COVID-19...

11 February 2022

News release

South Africa's mRNA hub progress is foundation for self-reliance

...The mRNA global hub is designed to serve low- and middle-income countries and will empower countries to not only be able to make their own mRNA vaccines but ultimately to have the choice of which vaccines they want to make. Manufacturers from low- and middle-income countries are therefore encouraged to express their own interest so they can receive training, technology transfer and any necessary licenses. WHO and partners will bring in the production know-how, quality control and necessary licenses to a single entity to facilitate a broad and rapid technology transfer to multiple recipients.

"The pandemic has highlighted the need for increased local production of vaccines globally, especially in low- and middle-income countries," said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization. "The WHO mRNA global hub is a major step in that direction, by sharing technology and building on the capacity and scientific expertise that already exists in South Africa."

The global hubs will act as training facilities where technology is established at industrial scale and clinical development performed. WHO will compliment this activity and assist other countries in Africa and other low- and middle-income countries to strengthen biomanufacturing capacity as well as regulatory capacity...

11 February 2022
Departmental news

[WHO's new International Classification of Diseases \(ICD-11\) comes into effect](#)

11 February 2022
Highlights

[ICD-11 2022 release](#)

The International Classification of Diseases (ICD) provides a common language that allows health professionals to share standardized information across the world. The eleventh revision contains around 17 000 unique codes, more than 120 000 codable terms and is now entirely digital.

11 February 2022
Departmental news

[WHO mourns Dr Mwelecele Ntuli Malecela](#)

It is with a deep sense of sadness and sorrow that WHO is announcing the passing on 10 February 2022 of Dr Mwelecele Ntuli Malecela, Director of WHO's Department of Control of Neglected Tropical Diseases. Dr Malecela died after a prolonged illness at the age of 58.

Dr Malecela will be remembered as an inspirational figure, a dedicated leader and a committed listener...

9 February 2022
Departmental news

[France and WHO sign new agreement to reinforce health systems to combat COVID-19](#)

Lyon - The Government of France and WHO today announced a new €50 million contribution agreement that will help countries' health systems overcome bottlenecks in the COVID-19 response and speed up equitable access to testing, treatments and vaccines...

9 February 2022
Departmental news

[Ensuring artificial intelligence \(AI\) technologies for health benefit older people](#)

9 February 2022
News release

[ACT-Accelerator calls for fair share-based financing of US\\$ 23 billion to end pandemic as global emergency in 2022](#)

[See Perspectives above for detail]

8 February 2022
News release

[FIFA and WHO reiterate call on world to #ACTogether to end COVID-19 pandemic](#)

7 February 2022
Media release

[Commonwealth and WHO to strengthen cooperation on health, including access to vaccines](#)

Memorandum of Understanding agreement signed today focuses on ending the COVID-19 pandemic, advancing Universal Health Coverage, addressing vaccine equity, strengthening digital health systems and working towards global health security

7 February 2022
Departmental news

[Executive Board reviews progress in the implementation of the global road map on defeating meningitis by 2030](#)

7 February 2022
Departmental news

[Essential health services face continued disruption during COVID-19 pandemic](#)
[See Perspectives above for detail]

6 February 2022
Statement

[IOC and WHO reaffirm collaboration to promote vaccine equity and healthy lifestyles](#)

... The IOC and the WHO formalised their collaboration to promote public health with a Memorandum of Understanding in 1984. The partnership has grown since then, resulting in a series of projects promoting grassroots sports and healthy lifestyles for all, and leveraging WHO expertise in health emergency, mass gathering, and water quality in the context of the Olympic Games. The two organisations signed a new Cooperative Agreement in 2020 to strengthen and expand on these dimensions...

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [Africa on track to control COVID-19 pandemic in 2022](#) 10 February 2022

WHO Region of the Americas PAHO

:: [WHO's new International Classification of Diseases \(ICD-11\) comes into effect](#)

February 11, 2022 - The World Health Organization (WHO) Eleventh Revision of the International Classification of Diseases (ICD-11) has now come into effect, with the latest update going online today. The ICD provides a common language that allows health professionals to share standardized information across the world. It is the foundation...

:: [Despite overall drop in new infections this week, pandemic continues to challenge health care workers in the Americas](#)

PAHO warns that recent surge in COVID-19 cases has overburdened struggling systems. Countries must urgently increase staff and training and prioritize health care workers for vaccination. Washington D.C. February 9, 2022 (PAHO) – While cases of COVID-19 fell by a third in the Americas this week, health care workers continue to face challenging...

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: [WHO/Europe urges governments to include young people in decisions about their health](#) 11-02-2022

:: ["Patients should be co-developers of digital health apps": Polina's story about fighting disease with innovation](#) 08-02-2022

WHO Eastern Mediterranean Region EMRO

No new digest content identified

WHO Western Pacific Region

No new digest content identified

.....

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

[SAVE THE DATE - What recent evidence do we have that omicron is evading immunity and what are the implications?](#)

14 February 2022 13:00 – 17:15 CET

[Webinar to present the WHO Classification of self-care interventions](#)

14 February 2022 15:00 – 16:30 UTC Time

[Provision of essential Services to Migrants: Promising practices and Emerging Challenges](#)

15 February 2022 11:00 – 12:00 CET

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

10 February 2022

[Assessed contributions overview for all Member States as at 31 December 2021](#)

10 February 2022

[Meetings of the malaria elimination certification panel \(MECP\): report of two virtual meetings, 3-4...](#)

10 February 2022

[Malaria Vaccine Advisory Committee \(MALVAC\) meeting on Preferred Product Characteristics for malaria...](#)

9 February 2022

[Ageism in artificial intelligence for health](#)

9 February 2022

[Codex 2021: a year of virtual reality](#)

8 February 2022

[Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19...](#)

.....
.....
.....

CDC/ACIP [U.S.] [to 12 Feb 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[New CDC Studies: COVID-19 Boosters Remain Safe, Continue to Offer High Levels of Protection Against Severe Disease Over Time and During Omicron and Delta Waves](#)

Friday, February 11, 2022

.....

[ACIP Meetings](#)

Next meeting scheduled for February 23-24, 2022

Draft Agenda – February 23-24, 2022

.....

[MMWR News Synopsis Friday, February 11, 2022](#)

Selected Content

:: Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2012–2020

:: Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022

:: Previously Released: Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021

:: Previously Released: Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

- 2/11/22 [New CDC Studies: COVID-19 Boosters Remain Safe, Continue to Offer High Levels of Protection Against Severe Disease Over Time and During Omicron and Delta Waves](#)
- 2/11/22 [EARLY RELEASE: Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022](#)
- 2/11/22 [EARLY RELEASE: Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022](#)
- 2/11/22 [Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 11 Feb 2022 06:00:00 EST...](#)

.....

.....

Africa CDC [to 12 Feb 2022]

<http://www.africacdc.org/>

News

[Africa CDC COVID-19 Brief 08 Feb 22 – AR](#)

.....

.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 12 Feb 2022]

<http://en.nhc.gov.cn/>

News

[Feb 12: Daily briefing on novel coronavirus cases in China](#)

On Feb 11, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 99 new cases of confirmed infections.

National Medical Products Administration – PRC [to 12 Feb 2022]

<http://english.nmpa.gov.cn/>

News

[Over 3.02b COVID-19 vaccine doses administered on Chinese mainland](#)

2022-02-11

More than 3.02 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Feb 10.

CCDC [Weekly Reports: Current Volume \(4\)](#)

2022-02-11 / No. 6

[View PDF of this issue](#)

:: [Perspectives: Application of Blockchain in Trusted Digital Vaccination Certificates](#)

:: [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, December 2021](#)

.....

.....

.....

Contents [click to move among sections]

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 12 Feb 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

No new digest content identified.

Paul G. Allen Frontiers Group [to 12 Feb 2022]

<https://alleninstitute.org/news-press/>

News

Press Release

[The Paul G. Allen Frontiers Group announces 23 new Allen Distinguished Investigators](#)

February 9, 2022

\$15.5M in research funding will support cutting-edge projects in mammalian synthetic biology, the neuroscience of under-studied animals, and tiny proteins involved in immunity

BMGF - Gates Foundation [to 12 Feb 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 12 Feb 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of

mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 12 Feb 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 12 Feb 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: **[Informed Consent: A Monthly Review – February 2022](#)** is now posted [here](#)

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)**

CEPI – Coalition for Epidemic Preparedness Innovations [to 12 Feb 2022]

<http://cepi.net/>

Latest News

[CEPI, Shanghai Zerun Biotech and Walvax Biotech expand collaboration to develop COVID-19 multi-variant vaccine](#)

OSLO, Norway, SHANGHAI and KUNMING, China; 8 February 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will expand its collaboration with Shanghai Zerun Biotechnology Co., Ltd. (Zerun Bio) and its parent company Walvax Biotechnology Co., Ltd. (Walvax), a public company listed on the Shenzhen Stock Exchange (300142.SZ) to advance the development of a COVID-19 variant vaccine. CEPI will invest up to an additional USD\$8.15 million to support a Phase I/II clinical trial in Mali which will evaluate the safety and immunogenicity of Zerun Bio's prototype and multi-variant vaccine candidates. This will be the first clinical trial of the multi-variant vaccine, which has the potential to provide protection against a broad range of COVID-19 variants.

Including this latest funding, CEPI has now committed up to USD\$25.1 million to this vaccine development partnership to support preclinical studies, early-stage clinical trials, process optimization and manufacturing scale-up of prototype and multi-variant vaccines...

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 12 Feb 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 12 Feb 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 12 Feb 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 12 Feb 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 12 Feb 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 12 Feb 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

New Resources

[**Interventions to prevent persistent post-COVID-19 olfactory dysfunction \(search on 16 December 2020\) Added February 11, 2022**](#)

[**COVID-19 vaccination intention in the first year of the pandemic \(search up to 31 December 2020\) Added February 7, 2022**](#)

Fondation Merieux [to 12 Feb 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 12 Feb 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 12 Feb 2022]
<https://www.ghitfund.org/newsroom/press>
No new digest content identified.

Global Fund [to 12 Feb 2022]
<https://www.theglobalfund.org/en/news/>
News & Stories

[Call for Applications for New Global Fund Independent Evaluation Panel](#)

11 February 2022

The Global Fund's independent evaluation function is being transformed in order to strengthen accountability and learning, based on the results of independent evaluations. The objective is to ensure that evaluations are relevant, timely and of high quality, driving us closer to achieving our goal of ending HIV, TB and malaria as epidemics.

The Global Fund is inviting applications for its new Independent Evaluation Panel (IEP), a body of around ten members that will replace the current Technical Evaluation Reference Group (TERG) at the end of 2022...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 12 Feb 2022]

<https://www.glopid-r.org/news/>
News

[GloPID-R and UK DHSC organise funders' roundtable to strengthen the clinical trials ecosystem](#)

11/02/2022

Funders play a critical role in clinical trials, representing a major force in improving trial coordination during global health emergencies... The roundtable highlighted that sustained coordination, flexibility, efficiency and the translation of findings into policy are essential to promote high-quality clinical research during and between global health emergencies. Also, for global research collaboration to be achieved, research capacity must be strengthened in low- and middle-income countries. The Forum demonstrated the key role of funders in achieving this...

Hilleman Laboratories [to 12 Feb 2022]
<http://www.hillemanlabs.org/>
News & Insights

[HILLEMAN VACCINES & BIOLOGICS SYMPOSIUM - 23 February 2022](#)

[agenda](#)
[register](#)

HHMI - Howard Hughes Medical Institute [to 12 Feb 2022]
<https://www.hhmi.org/news>
Press Room
Research Feb 8 2022

[Nasal Spray Booster Keeps COVID-19 at Bay](#)

In mice, a vaccination strategy that uses an mRNA coronavirus vaccine injection followed by a nasal spray booster generates immune protection in the airways.

Human Vaccines Project [to 12 Feb 2022]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 12 Feb 2022]

<https://www.iavi.org/>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 12 Feb 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

No new digest content identified.

Institut Pasteur [to 12 Feb 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 12 Feb 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

11 Feb 2022

[**New Study Highlights Social Media's Key Role in COVID-19 Vaccine Uptake for Migrants**](#)

Berlin – Governments could close COVID-19 vaccination gaps by breaking down language barriers and giving migrants easier access to information particularly through social media, according to a [study](#) published today by the International Organization for Migration (IOM) and the University of Potsdam.

Studies from several countries in the US and Europe, including Germany, suggest that vaccination rates are lower among migrant communities compared to the general population. Gaps may vary by country and group but a recent study by the Robert Koch Institute in Germany revealed that the vaccination rate among migrants is 8 per cent lower compared to the native-born population. The study argues that such vaccination gaps may be linked to language barriers, socioeconomic status, and misinformation among migrant communities.

IOM's Global Migration Data Analysis Centre ([GMDAC](#)) and the University of Potsdam tested the effect of language and trust barriers in Germany via a social media campaign in their study, "Promoting COVID-19 vaccination uptake among migrant communities on social media – Evidence from Germany". "More evidence on the interlinkage between migration and health is urgently needed," said GMDAC Director Frank Laczko. "Many countries around the world have large migrant populations, yet many of them do not consider the needs of migrants sufficiently in their vaccination programmes." Expensive national campaigns to boost vaccine uptake using print, TV, and radio often neglect social media. The results of the study show how specific groups can be reached more effectively and at low cost...

ISC / International Science Council [to 12 Feb 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts

Blogs

[Celebrating women and girls who are leading the way in science and innovation - 11.02.2022](#)

Join us in celebrating today the 7th International Day of Women and Girls in Science, a day dedicated to remarkable women and girls around the world who are inventing the future and making the world a better place through the power of science. Female scientists who go beyond any barrier, forge new scientific paths and are at the forefront of achieving a much-needed gender equality in science...

IVAC [to 12 Feb 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

[IVAC and VALUE Baltimore Project Launch COVID-19 Information Compendium](#)

February 2022

The VALUE (Vaccine Acceptance & Access Live in Unity, Education, and Engagement) Baltimore Project, which aims to improve COVID-19 vaccine acceptance in Baltimore City, has created a new resource for anyone seeking up-to-date information about COVID-19. This free resource has six topic areas: COVID-19 Illness General Vaccine Information COVID-19 Vaccines COVID-19 Vaccine Policy COVID-19 Vaccines [...]

IVI [to 12 Feb 2022]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 12 Feb 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

[Applications Now Open for the Emerging Leaders in Biosecurity Fellowship Class of 2022](#)

February 9, 2022

MSF/Médecins Sans Frontières [to 12 Feb 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Sciences - USA [to 12 Feb 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 12 Feb 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 12 Feb 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

[NIH-funded study suggests COVID-19 increases risk of pregnancy complications](#)

Monday, February 7, 2022

Pregnant women with COVID-19 appear to be at greater risk for common pregnancy complications — in addition to health risks from the virus — than pregnant women without COVID-19, suggests a study funded by the National Institutes of Health.

OECD [to 12 Feb 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

No new digest content identified.

PATH [to 12 Feb 2022]

<https://www.path.org/media-center/>

Press Releases

PATH Board of Directors announces annual officer elections

February 10, 2022 by PATH

PATH's Board of Directors is pleased to announce the appointment of new officers following its annual officer elections in December of 2021.

Beth Galetti, Senior Vice President of People Experience and Technology at Amazon, has been named Board Chair. Most recently, Galetti held the Vice Chair position as well as seats on the Executive and Audit Committees, and she has served on the PATH Board since 2018. At Amazon, Galetti leads a team that oversees the recruitment, growth, development, and support of more than one million employees in over 50 countries...

Sabin Vaccine Institute [to 12 Feb 2022]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 12 Feb 2022]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

9 February 2022

Networks led by young people in Asia and the Pacific find ways to adapt to COVID-19 and deal with uncertain futures

UNHCR Office of the United Nations High Commissioner for Refugees [to 12 Feb 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

No new digest content identified.

UNICEF [to 12 Feb 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

02/09/2022

ACT-Accelerator calls for fair share-based financing of US\$ 23 billion to end pandemic as global emergency in 2022

Remarks

02/08/2022

Remarks by UNICEF Executive Director Catherine M. Russell at the opening of the UNICEF Executive Board

As prepared for delivery

Unitaid [to 12 Feb 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

USAID [to 12 Feb 2022]

<https://www.usaid.gov/news-information/press-releases/2021>

Selected Press Releases, Statements, Announcements

News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 12 Feb 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 12 Feb 2022]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 12 Feb 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 12 Feb 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 12 Feb 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 12 Feb 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 12 Feb 2022]

<https://www.wfpha.org/>

Latest News - Blog

Event

What Is Leadership in a Pandemic?

Feb 7, 2022

...On February 16, 2022, at 13:00 – 14:30 (CET), global public health leaders, working within the framework of the WFPHA, will discuss concrete actions to promote equity, public health leadership and global coordination to address pressing global health challenges, including the COVID-19 pandemic and other health threats. [Register](#)

World Bank [to 12 Feb 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Solid Waste Management

Context Around the world, waste generation rates are rising. In 2016, the worlds' cities generated 2.01 billion tons of solid waste, amounting to a footprint of 0.74 kilograms per person per...

Date: February 11, 2022 Type: Brief

Greater and More Diverse Participation in Global Trade is Key to Achieving Africa's Economic Transformation, says New World Bank Book

ACCRA, February 10, 2022 – African countries must expand and diversify their participation in international trade and global value chains to reduce poverty on a large scale and transform their economies...

Date: February 10, 2022 Type: Press Release

The World Bank's Blue Economy Program and PROBLUE: Supporting integrated and sustainable economic development in healthy oceans

What is PROBLUE? PROBLUE is an Umbrella Multi-Donor Trust Fund (MDTF) administered by the World Bank, designed to help countries chart a course towards a blue economy approach. A blue economy refers to...

Date: February 10, 2022 Type: Brief

New World Bank Report Identifies Reforms to Improve Public Expenditure for Human Capital

KATHMANDU, February 9, 2022 – Nepal has made significant progress in human capital development, though key challenges remain in the health, education, and social protection sectors, which have been...

Date: February 09, 2022 Type: Press Release

COVID-19 Pandemic Leads to Innovations in Education in Saudi Arabia

Six million children benefited from Saudi Arabia's innovative distance learning platform "Madrasati" RIYADH, February 8, 2022 — School closures due to the pandemic led to 6 million children being part...

Date: February 08, 2022 Type: Press Release

World Organisation for Animal Health (OIE) [to 12 Feb 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

Digital transformation and the OIE Observatory: A synergic approach

Editor's Choice

9 February 2022

Digital transformation is identified as a key objective in the World Organisation for Animal Health's (OIE's) Seventh Strategic Plan, and is an important response to the need to become a more modern and agile organisation. This is a vital shift in view of the increasing use of information technologies to support regulation for animal health, animal welfare and veterinary public health...

At present, the OIE is defining its expectations of data stewardship through the establishment of a data governance framework. These expectations include demonstrating responsible management of data and enhancing access to data for Members while respecting concerns for privacy and intellectual property. This work will provide essential organisation-wide rules and processes while also determining the development and direction of each of our key information systems, including those contributed to regularly by OIE Members..

WTO - World Trade Organisation [to 12 Feb 2022]

http://www.wto.org/english/news_e/news_e.htm


WTO News and Events

Workshop looks into practical aspects of supporting equitable access to COVID-19 vaccines

11 February 2022

Over 250 representatives from WTO members and observers participated on 11 February in a technical workshop focused on the practical aspects of COVID-19 vaccine research and development (R&D), manufacturing, regulatory approval, distribution, and coordination of vaccination campaigns. WTO Deputy Director-General Anabel González hosted the event...The video of the session is available [here](#). The programme, speakers' biographies and background materials are available [here](#).

Selected slides from meeting:



WTO Technical Workshop on Covid-19 Vx R&D, Manufacturing and Distribution

11 February 2022: 13:00-15:00 CET


Carmen Rodriguez | Team Lead, Vaccine Prequalification, Department of Regulation and Prequalification (RPQ)

Emergency regulatory authorizations issued by >150 LMI countries/territories

update: as of 01 February 2022

<u>AZ (incl. SII)</u> 142 countries/territories 1470 regulatory clearance 8 DS sites 12 DP sites	<u>Janssen</u> 115 countries/territories 786 regulatory clearance 3 DS sites 7 DP sites	<u>Moderna</u> 77 countries/territories 500 regulatory clearance 2 DS sites 3 DP sites	<u>Pfizer</u> 156 countries/territories 299 regulatory clearance 4 DS sites 10 DP sites	<u>Sinopharm</u> 80 countries/territories 80 regulatory clearance 1 DS/DP site	<u>Sinovac</u> 61 countries/territories 90 regulatory clearance 1 DS/DP site	<u>Novavax</u> 34 countries/territories 34 regulatory clearance 1 DS/DP site
Viral vector		mRNA		Inactivated		Protein subunit

This has been the fastest, most complex vaccine introduction globally in history



Session 5: Getting vaccines into arms

Dr. Ann Lindstrand, Unit Head, EPI /IVB/WHO
Covid-19 Vaccine Delivery Partnership

February 2022

Bottlenecks

Political Context and In-Country Planning Mechanisms

- Leadership and Coordination; Lack of supply visibility; Multiple products, short shelf-life, cold chain capacity; Data and data management; Competing priorities.

Financing

- Country-level inadequate budgets for COVID-19 vaccination operational and vaccine purchase need; Donor money is committed but slow to reach countries, and often slowly trickle down to facilities and front-line providers; Some countries are reluctant to apply for MDB loans, and/or lack time and capacity to apply for GAVI funding

Demand and Hesitancy

- Lack of trust in governments and health systems; Lack of access to vaccination sites/lack of awareness of where to get vaccine.

Health Workforce

- Loss of health workforce due to infections, deaths, quarantine, labor protests, and strikes and Covid 19 response; Acute shortages in staffing that existed even prior to the pandemic; Lack of training on COVID-19 vaccines which has contributed to hesitancy among health worker.

In-Country Supply Chain

- Insufficient cold chain capacity at sub-national and district levels, including no ultra-cold chain capacity for many countries.

Data Systems

- Lack of data systems at country level to determine eligibility, schedule appointments, and track vaccination status; Infrequent data collection and reporting (often monthly).



WTO members, international organizations outline Aid for Trade activities amid COVID-19

8 February 2022

An overview of recent Aid for Trade activities was given by WTO members, international financial institutions and observer organisations at a session of the Committee on Trade and Development on 8 February dedicated to the Aid for Trade initiative. A workshop organized by the Committee on 7 February explored how the COVID-19 pandemic has accelerated the shift towards the digital economy and the constraints that developing countries face.

DDG Ellard: Multilateralism is the solution to challenges of global commons, unilateralism

7 February 2022

Deputy Director-General Angela Ellard delivered a lecture to the US National War College on 7 February in which she discussed economic multilateralism as a potent instrument of economic power. She addressed the historical context and basic principles of the WTO as well as the modern challenges facing the organization and the multilateral trading system.

.....

ARM [Alliance for Regenerative Medicine] [to 12 Feb 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 12 Feb 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 12 Feb 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 12 Feb 2022]

<https://internationalbiotech.org/news/>

News

Website in "maintenance mode"

IFPMA [to 12 Feb 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[Position paper - Use of electronic labeling](#)

07 February 2022

"E-labeling will increasingly play a role in facilitating fast deployment of product information and facilitate patient understanding and adherence.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

[IGBA establishes a CEO Advisory Committee \(February 2022, Committee updated\)](#)

The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States.

Committee members are:

Chirag Patel, President and Co-Chief Executive Officer - Amneal Pharmaceuticals Inc.

Jeff Watson, President and Chief Executive Officer - Apotex Inc.

Pankaj Patel, Chairman - Cadila Healthcare Ltd.

Samina Hamied, Executive Vice-Chairperson - Cipla Ltd.

Satish Reddy, Chairman - Dr. Reddy's Laboratories Ltd.

Lucas Sigman, Chief Executive Officer - Insud Pharma S.L.

Vinita Gupta, Chief Executive Officer - Lupin Ltd.

Markus Sieger, Chief Executive Officer - Polpharma Group

Richard Saynor, Chief Executive Officer - Sandoz AG

Peter Goldschmidt, Chief Executive Officer and Chairman Executive Board - STADA Arzneimittel AG

Dilip Shanghvi, Managing Director - Sun Pharmaceutical Industries Ltd.

Kåre Schultz, President and Chief Executive Officer - Teva Pharmaceuticals Industries Ltd.

David Peix, Chief Executive Officer - Towa Pharma International Holdings S.L.

Michael Goettler, Chief Executive Officer - Viatris Inc.

This Committee provides a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues...

International Alliance of Patients' Organizations – IAPO [to 12 Feb 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 12 Feb 2022]

<http://www.phrma.org/>

Latest News [Selected]

[Takeda's Ramona Sequeira Becomes Board Chair of PhRMA](#)

Feb 9, 2022

The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Ramona Sequeira, President of Takeda's U.S. Business Unit and Global Portfolio Commercialization, has assumed the role of chair of the PhRMA Board of Directors.

*

*

*

*

Contents [click to move among sections]

::

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some

editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 1: E1-105 Jan 2022

<https://journalofethics.ama-assn.org/issue/inequity-along-medicaldental-divide>

Inequity Along the Medical/Dental Divide

Dental and medical health systems in the United States have evolved as fully separate entities. This division exacerbates health inequity, since patients' poor oral health affects their general health. The professionally entrenched view that what's in patients' mouths is somehow isolated from what's going on in the rest of their bodies is one all clinicians need to resist, since this view can be a source of harm, particularly among vulnerable patients and communities. Practical and ethical strategies for better aligning medical and dental goals of care are considered in this issue.

[Reviewed earlier]

American Journal of Infection Control

February 2022 Volume 50 Issue 2 p123-242

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

February 2022 Volume 62 Issue 2 p149-306

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

February 2022 112(2)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2022 Volume 175, Issue 1

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 303 February 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/302/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMJ Global Health

February 2022 - Volume 7 - 2

<https://gh.bmj.com/content/7/1>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 12 Feb 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 12 Feb 2022)

[The impact of COVID-19 and associated measures on health, police, and non-government organisation service utilisation related to violence against women and children](#)

Globally, concerns have been raised that the priority implementation of public health measures in response to COVID-19 may have unintended negative impacts on a variety of other health and wellbeing factors, i...

Authors: Nadia Butler, Zara Quigg, Isabelle Pearson, Zhamin Yelgezekova, Aasa Nihlén, Mark A. Bellis, Yongjie Yon, Jonathon Passmore, Isabel Yordi Aguirre and Heidi Stöckl

Citation: BMC Public Health 2022 22:288

Content type: Research

Published on: 12 February 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 12 Feb 2022)

[Global research alliance in infectious disease: a collaborative effort to combat infectious diseases through dissemination of portable sequencing](#)

To disseminate the portable sequencer MinION in developing countries for the main purpose of battling infectious diseases, we found a consortium called Global Research Alliance in Infectious Diseases (GRAID). ...

Authors: Lucky R. Runtuwene, Nuankanya Sathirapongsasuti, Raweewan Srisawat, Narumon Komalamisra, Josef S. B. Tuda, Arthur E. Mongan, Gabriel O. Aboge, Victoria Shabardina, Wojciech Makalowski, Dela Ria Nesti, Wayan T. Artama, Lan Anh Nguyen-Thi, Kiew-Lian Wan, Byoung-Kuk Na, William Hall, Arnab Pain...

Citation: BMC Research Notes 2022 15:44

Content type: Research note

Published on: 12 February 2022

BMJ Evidence-Based Medicine

February 2022 - Volume 27 - 1

<https://ebm.bmj.com/content/27/1>

[Reviewed earlier]

BMJ Open

February 2022 - Volume 12 - 2

<https://bmjopen.bmj.com/content/12/2>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(2); 2022 Feb 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/399608/>

[Reviewed earlier]

Cell

Feb 03, 2022 Volume 185 Issue 3 p401-578

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 48, Issue 1 Pages: 1-175 January 2022

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 2 Pages: 333-518 February 2022

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

December 2021 Volume 43 Issue 12 p2041-2172

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 12 Feb 2022]

[No new digest content identified]

Contemporary Clinical Trials

Volume 113 February 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/113/suppl/C>

Research article Open access

Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days

Erin K. McCreary, J. Ryan Bariola, Tami Minnier, Richard J. Wadas, ... Derek C. Angus
Article 106652

The CRISPR Journal

Volume 4, Issue 6 / December 2021

<https://www.liebertpub.com/toc/crispr/4/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2022 - Volume 35 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 1 Pages: 1-298 January 2022
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 23 Issue 2 3 February 2022
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 28, Number 2—February 2022
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 37 December 2021
<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 150 - 2022
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[New issue; No digest content identified]

Ethics & Human Research

Volume 44, Issue 1 Pages: 1-39 January–February 2022
<https://onlinelibrary.wiley.com/toc/25782363/current>
[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021
<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender

equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.
[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 20 February 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/20/suppl/C>

[New issue; No digest content identified]

The European Journal of Public Health

Volume 32, Issue 1, February 2022

<https://academic.oup.com/eurpub/issue/32/1>

[New issue; No digest content identified]

Expert Review of Vaccines

Vol 21 (1) 2022

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 12 Feb 2022]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 4 December 31, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 12 Feb 2022]

Article

[Austria: General COVID-19 Vaccine Mandate Enters into Force](#)

On February 5, 2022, a general COVID-19 vaccine mandate entered into force in Austria for every Austrian resident 18 years or older. No direct coercion will be used to enforce it, meaning no one will be imprisoned for noncompliance; only administrative fines will be imposed. The COVID-19 Mandatory Vaccination Act (Act) will be automatically repealed ... Continue reading "Austria: General COVID-19 Vaccine Mandate Enters...

Contributor: Gesley, Jenny

Date: 2022-02-10

Global Public Health

Volume 17, Issue 2 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 12 Feb 2022]

[Vaccine nationalism will persist: global public goods need effective engagement of global citizens](#)

Authors: Stuart J. Peacock

Content type: Debate

12 February 2022

Abstract

Covid-19 presents a unique opportunity to transform democratic engagement in the governance of global public goods. In this paper, I describe a global public goods framework and how it relates to Covid-19 vaccines, and summarize some of the global responses to Covid-19. I discuss some of the global threats to health and prosperity posed by the inequitable distribution of vaccines, and propose transformative thinking to democratically engage citizens in the governance of global public goods. In recent years, public-private partnerships and philanthropic organizations have successfully stepped in to help international organizations like the UN and WHO provide global public goods, but they are not democratically elected or publicly accountable. Global public goods are critical to addressing Covid-19, future pandemic preparedness, global health policy, health equity, and the unfolding climate crisis. To make us more resistant and resilient to future global health crises we need transformative thinking to democratically engage global citizens. We need to lay the foundations for a 'global social contract' on global public goods.

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Special Issue 1 - January 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: Country Responses to the COVID-19 Pandemic

Articles analyzing country responses in Australia, New Zealand, Canada, U.S., Belgium, Netherlands, Sweden, France, Italy

Health Policy and Planning

Volume 37, Issue 2, February 2022

<https://academic.oup.com/heapol/issue/37/2>

ORIGINAL ARTICLES

Public finance of universal routine childhood immunization in India: district-level cost estimates

Emily Schueller, Arindam Nandi, Amit Summan, Susmita Chatterjee, Arindam Ray ...

Health Policy and Planning, Volume 37, Issue 2, February 2022, Pages 200–208,

<https://doi.org/10.1093/heapol/czab114>

COVID-19 Preparedness and Response Plans from 106 countries: a review from a health systems resilience perspective

Saqif Mustafa, Yu Zhang, Zandile Zibwowa, Redda Seifeldin, Louis Ako-Egbe ...

Health Policy and Planning, Volume 37, Issue 2, February 2022, Pages 255–268,

<https://doi.org/10.1093/heapol/czab089>

REVIEW

Understanding the complexity of demand-side determinants on vaccine uptake in sub-Saharan Africa

Phylisha G van Heemskerken, Catherine J Decouttere, Henk Broekhuizen, Nico J Vandaele

Health Policy and Planning, Volume 37, Issue 2, February 2022, Pages 281–291,

<https://doi.org/10.1093/heapol/czab139>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 12 Feb 2022]

[No new digest content identified]

Human Gene Therapy

Volume 33, Issue 1-2 / January 2022

<https://www.liebertpub.com/toc/hum/33/1-2>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Online Article

Embedding ethics in the practice of humanitarian innovation

by Ian McClelland and Matthew Hunt
20 January 2022

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 11, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Feb 08, 2022 Volume 55 Issue 2 p185-376

<https://www.cell.com/immunity/current>

Perspective

SARS-CoV-2 infections in children: Understanding diverse outcomes

Petter Brodin

Open Access

Brodin summarizes the current understanding of immune responses to SARS-CoV-2 infections in children and the possible explanations for the overall milder COVID-19 disease in young versus older individuals. To explain the combined observations to date, Brodin proposes an energy allocation perspective to explain mild disease, viral dynamics, and MIS-C in children and young people.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 12 Feb 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 12 Feb 2022]

[No new digest content identified]

International Health

Volume 14, Issue 1, January 2022

<https://academic.oup.com/inthealth/issue/14/1>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022
<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>
[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 6, December 2021
<https://academic.oup.com/ije/issue>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>
Table of Contents
[Reviewed earlier]

JAMA

February 8, 2022, Vol 327, No. 6, Pages 503-597
<https://jamanetwork.com/journals/jama/currentissue>
Caring for the Critically Ill Patient

[Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19](#)

Hidde Heesakkers, MD; Johannes G. van der Hoeven, MD, PhD; Stijn Corsten, MD; et al.
free access has active quiz
JAMA. 2022;327(6):559-565. doi:10.1001/jama.2022.0040

This exploratory prospective cohort study assesses the occurrence of physical, mental, and cognitive symptoms among ICU patients in the Netherlands who survived COVID-19 at 1 year following hospitalization.

Research Letter

[Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves](#)

Caroline Maslo, MD, PhD; Richard Friedland, MD, BVSc; Mande Toubkin, RN, RM, Rpaeds; et al.
free access has active quiz
JAMA. 2022;327(6):583-584. doi:10.1001/jama.2021.24868

This study describes the characteristics and clinical outcomes of patients hospitalized in South Africa during the Omicron wave compared with the same variables from earlier COVID-19 waves.

[US Insurer Spending on Ivermectin Prescriptions for COVID-19](#)

Kao-Ping Chua, MD, PhD; Rena M. Conti, PhD; Nora V. Becker, MD, PhD
free access has active quiz
JAMA. 2022;327(6):584-587. doi:10.1001/jama.2021.24352

This study examines insurer coverage of ivermectin prescriptions for COVID-19 in the US.

JAMA Network

COVID-19 Update February 12, 2022

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

February 2022, Vol 176, No. 2, Pages 115-212

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Research Letter

Association of Discrimination and Health Care Experiences With Incomplete Infant Vaccination During COVID-19

Heidi Preis, PhD; Marci Lobel, PhD; Brittain Mahaffey, PhD; et al.

free access has active quiz

JAMA Pediatr. 2022;176(2):196-198. doi:10.1001/jamapediatrics.2021.4710

This observational analysis explores how the COVID-19 pandemic contributed to a decrease in infant vaccinations.

Intention to Vaccinate Children Against COVID-19 Among Vaccinated and Unvaccinated US Parents

Madhura S. Rane, PhD; McKaylee M. Robertson, PhD; Drew A. Westmoreland, PhD; et al.

free access has active quiz

JAMA Pediatr. 2022;176(2):201-203. doi:10.1001/jamapediatrics.2021.5153

This study examines parental intention to vaccinate children against COVID-19 and related sociodemographic factors in a national sample of US parents.

State Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization

Ashlynn R. Torres, BA; Nicholas P. Johnson, MPH; Mallory K. Ellingson, MPH; et al.

JAMA Pediatr. 2022;176(2):203-205. doi:10.1001/jamapediatrics.2021.4591

This national cohort study examines National Immunization Survey–Teen to assess the association of adolescents' ability to consent to human papillomavirus vaccination without parental involvement with vaccination rates.

JB I Evidence Synthesis

January 2022 - Volume 20 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

February 2022 Volume 70 Issue 2 p171-350

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 47, issue 1, February 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-1>

Articles

[A Multilevel Intervention to Increase HPV Vaccination among Asian American Adolescents](#)

Authors (first, second and last of 9)

Grace X. Ma, Lin Zhu, Min Qi Wang

Content type: Original Paper

Open Access

Published: 07 July 2021

Pages: 9 - 16

[Parental Perspectives on Immunizations: Impact of the COVID-19 Pandemic on Childhood Vaccine Hesitancy](#)

Authors (first, second and last of 5)

Kaidi He, Wendy J. Mack, Vikram Anand

Content type: Original Paper

Published: 23 July 2021

Pages: 39 - 52

[Increasing Human Papillomavirus Vaccination in a Federally Qualified Health Center Organization Using a Systems-Based Intervention Integrating EHR and Statewide Immunization Information System](#)

Authors (first, second and last of 7)

Debra M. Vinci, Jessica Ryan, Rebecca McClain

Content type: Original Paper

Open Access

Published: 31 July 2021

Pages: 53 - 62

[Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic](#)

Authors (first, second and last of 5)

Lindsay Podraza, Jayan Vasudevan, Meera Varman

Content type: Original Paper

Published: 13 August 2021

Pages: 87 - 93

Journal of Development Economics

Volume 155 March 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/155/suppl/C>

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2022 - Volume 76 - 2

<https://jech.bmj.com/content/76/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 2, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 4, November 2021

<https://muse.jhu.edu/issue/46802>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 24, issue 1, February 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-1>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 225, Issue 1, 1 January 2022

<https://academic.oup.com/jid/issue/225/1>

[Reviewed earlier]

Journal of Medical Ethics

February 2022 - Volume 48 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

February 2022 Volume 241 p1-266

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 12 Feb 2022]

[No new digest content identified]

Journal of Public Health Management & Practice

January/February 2022 - Volume 28 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

February 2022 Volume 19 Issue 187

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 1, January 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 1 January 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Feb 12, 2022 Volume 399 Number 10325 p605-694

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Offline: Complacency threatens progress against COVID-19](#)

Richard Horton

Hans Kluge, WHO's Regional Director for Europe, has been reported as saying that European nations could soon be entering a "long period of tranquillity" as the pandemic abates. Pointing out that mortality from COVID-19 seemed to be plateauing, he suggested the continent was approaching a "plausible endgame" and an "enduring peace". As WHO's chief spokesperson for the 53 countries that make up his regional responsibility, Kluge was no doubt seeking to strike an optimistic and encouraging note. But it is disappointing that he took such a narrow geographical perspective about a global pandemic. His words promote a false reassurance that could breed complacency, even conceit...

Articles

[Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis](#)

Antimicrobial Resistance Collaborators

Open Access

[Casirivimab and imdevimab in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial](#)

RECOVERY Collaborative Group

Open Access

Seminar

[Measles](#)

Judith M Hübschen, Ionela Gouandjika-Vasilache, Julia Dina

The Lancet Child & Adolescent Health

Feb 2022 Volume 6 Number 2 p71-136, e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Feb 2022 Volume 4 Number 2 e75-e148

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Feb 2022 Volume 10 Number 2 e154-e297

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Feb 2022 Volume 22 Number 2 p151-296, e41-e65

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Feb 2022 Volume 7 Number 2 e93-e194

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Feb 2022 Volume 10 Number 2 p121-220, e11-e24

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 26, issue 1, January 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-1>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 2, February 2022

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 4 Pages: 853-1206 December 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 602 Issue 7896, 10 February 2022

<https://www.nature.com/nature/volumes/602/issues/7896>

Editorial | 08 February 2022

Long COVID and kids: more research is urgently needed

Like adults, children can experience long COVID, but few studies of the condition include young people. That has to change.

Editorial | 09 February 2022

Africa is bringing vaccine manufacturing home

A major milestone was reached last week when scientists in South Africa reproduced Moderna's COVID-19 vaccine. COVID-19 patents must now be shared.

Article / 22 December 2021 | Open Access

Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

The Alpha variant of SARS-CoV-2 outcompetes progenitor SARS-CoV-2 in upper respiratory tract replication competition in vivo.

Lorenz Ulrich, Nico Joel Halwe, Charaf Benarafa

Article | 22 December 2021 | Open Access

Local and systemic responses to SARS-CoV-2 infection in children and adults

Mechanisms explaining the milder clinical syndrome that is observed in children with SARS-CoV-2 infection.

Masahiro Yoshida, Kaylee B. Worlock, Kerstin B. Meyer

Nature Biotechnology

Volume 40 Issue 1, January 2022

<https://www.nature.com/nbt/volumes/40/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 12 Feb 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 2, February 2022

<https://www.nature.com/ng/volumes/54/issues/2>

Editorial | 11 February 2022

Our genes, our microbes

In recent years, large-scale genomic studies have been performed in attempts to determine how genetic variation in the human host influences the gut microbiome. As microbiome traits are very heterogeneous, new analytical approaches are needed to move this field forward. By using genetic

tools, there is a huge opportunity to enrich our understanding of the complex link between humans and our intimately associated microbial species.

Perspective | 03 February 2022

[Challenges and future directions for studying effects of host genetics on the gut microbiome](#)

This Perspective discusses the analytical issues concerning heterogeneity and power encountered in microbial genome-wide association studies and highlights potential future directions for genetic analysis of the microbiome.

Serena Sanna, Alexander Kurilshikov, Alexandra Zhernakova

Nature Human Behaviour

Volume 6 Issue 1, January 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/1>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 1, January 2022

<https://www.nature.com/nm/volumes/28/issues/1>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 2, February 2022

<https://www.nature.com/nrg/volumes/23/issues/2>

[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 2, February 2022

<https://www.nature.com/nri/volumes/22/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 2, February 2022

<https://www.nature.com/nrd/volumes/21/issues/2>

[Reviewed earlier]

New England Journal of Medicine

February 10, 2022 Vol. 386 No. 6

<https://www.nejm.org/toc/nejm/medical-journal>

Original Articles

[Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients](#)

A. Jayk Bernal and Others

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

L.M. Dunkle and Others

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America.

Editorials

Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19

R. Whitley

Audio Interview: Covid-19 as an Endemic Disease

E.J. Rubin, L.R. Baden, and S. Morrissey

Pediatrics

Volume 149, Issue 2, February 1, 2022

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 40, issue 2, February 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-2>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 12 Feb 2022)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 12 Feb 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 12 Feb 2022)

Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland

Lauri Sääksvuori, Cornelia Betsch, Hanna Nohynek, Heini Salo, Jonas Sivelä, Robert Böhm

Research Article | published 09 Feb 2022 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003919>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 12 Feb 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 12 Feb 2022]

Research Article

[Perceptions of risk of SARS-CoV-2 transmission in social and educational activities by infectious diseases and general pediatric healthcare providers, a pre-vaccine risk perception cross-sectional survey](#)

Andrew B. Janowski, Philip M. Polgreen, Susan E. Beekmann, Jason G. Newland

Research Article | published 11 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263767>

[Factors affecting intention to take COVID-19 vaccine among Pakistani University Students](#)

Mosharop Hossian, Md Abdullah Saeed Khan, Anum Nazir, Mohammad Hayatun Nabi, Mehedi Hasan, Ramisha Maliha, Mohammad Ali Hossain, Md Utba Rashid, Nizwa Itrat, Mohammad Delwer Hossain Hawlader

Research Article | published 11 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0262305>

[Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population](#)

Yasmin Maor, Shaked Caspi

Research Article | published 11 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0255495>

[A method for estimating the impact of new vaccine technologies on vaccination coverage rates](#)

Ben Davis, Michael Krautmann, Pascale R. Leroueil

Research Article | published 10 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263612>

[Characterizing polarization in online vaccine discourse—A large-scale study](#)

Bjarke Mønsted, Sune Lehmann

Research Article | published 09 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263746>

[Misinformation, believability, and vaccine acceptance over 40 countries: Takeaways from the initial phase of the COVID-19 infodemic](#)

Karandeep Singh, Gabriel Lima, Meeyoung Cha, Chiyoungh Cha, Juhi Kulshrestha, Yong-Yeol Ahn, Onur Varol

Research Article | published 09 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263381>

The impact of the COVID-19 pandemic on scientific research in the life sciences

Massimo Riccaboni, Luca Verginer

Research Article | published 09 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263001>

The impact of risk perceptions and belief in conspiracy theories on COVID-19 pandemic-related behaviours

Jack P. Hughes, Alexandros Efstratiou, Sara R. Komer, Lilli A. Baxter, Milica Vasiljevic, Ana C. Leite

Research Article | published 08 Feb 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263716>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 12 Feb 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 11, 2022; vol. 119 no. 3

<https://www.pnas.org/content/119/3>

Biophysics and Computational Biology

Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave

Nathaniel Hupert, Daniela Marín-Hernández, Bo Gao, Ricardo Águas, and Douglas F. Nixon

PNAS January 18, 2022 119 (3) e2025448119; <https://doi.org/10.1073/pnas.2025448119>

Psychological and Cognitive Sciences

Open Access

Politicians polarize and experts depolarize public support for COVID-19 management policies across countries

Alexandra Flores, Jennifer C. Cole, Stephan Dickert, Kimin Eom, Gabriela M. Jiga-Boy, Tehila Kogut, Riley Loria, Marcus Mayorga, Eric J. Pedersen, Beatriz Pereira, Enrico Rubaltelli, David K. Sherman, Paul Slovic, Daniel Västfjäll, and Leaf Van Boven

PNAS January 18, 2022 119 (3) e2117543119; <https://doi.org/10.1073/pnas.2117543119>

Evolution

Open Access

Targeted vaccination and the speed of SARS-CoV-2 adaptation

Sylvain Gandon and Sébastien Lion

PNAS January 18, 2022 119 (3) e2110666119; <https://doi.org/10.1073/pnas.2110666119>

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 155 February 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/155/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

09 February 2022 Volume 289 Issue 1968

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 203 Pages 1-130 (February 2022)

<https://www.sciencedirect.com/journal/public-health/vol/203/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 137 Issue 1, January/February 2022

<https://journals.sagepub.com/toc/phrg/137/1>

Commentary

[Faith-Based Organizations and SARS-CoV-2 Vaccination: Challenges and Recommendations](#)

Jeff Levin, PhD, MPH, Ellen L. Idler, PhD, Tyler J. VanderWeele, PhD

First Published October 25, 2021; pp. 11–16

Topical Review

[Research Synthesis, HIV Prevention Response, and Public Health: CDC's HIV/AIDS Prevention Research Synthesis Project](#)

Linda J. Koenig, PhD, Cynthia M. Lyles, PhD, Darrel Higa, PhD, Mary M. Mullins, MSLS, Theresa A. Sipe, PhD, MPH for the HIV/AIDS Prevention Research Synthesis Project

First Published February 26, 2021; pp. 32–47

Law and the Public's Health

[Adolescent Consent to COVID-19 Vaccination: The Need for Law Reform](#)

Robert S. Olick, JD, PhD, Y. Tony Yang, ScD, LLM, MPH, Jana Shaw, MD, MPH

First Published September 21, 2021; pp. 163–167

Qualitative Health Research

Volume 32 Issue 3, February 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 12 Feb 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 12 Pages: 2177-2414 December 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 12 Feb 2022]

Original Research

[Epidemiological Characteristics and Transmission Patterns of COVID-19 Cases Among Children and Adolescents Aged 0–18 Years in South Korea](#)

Jang J, Hwang MJ, Kim YY, Park SY, Yoo M, Kim SS, Lee S, Kwon D

Published Date: 9 February 2022

Original Research

[Precise Community-Based Public Health Management: Crucial Experience Responding to COVID-19 in Wuhan, China](#)

Ran L, Tan X, Zhang Y

Published Date: 9 February 2022

Science

Volume 375| Issue 6581| 11 Feb 2022

<https://www.science.org/toc/science/current>

Policy Forum

EU and US legislation seek to open up digital platform data

BY Brandie Nonnecke, Camille Carlton

10 Feb 2022: 610-612

Free

Constraints on data access must be addressed to facilitate research

Reports

COVID mortality in India: National survey data and health facility deaths

BY Prabhat Jha, et al.

06 Jan 2022: 667-671

Open Access

India's cumulative COVID deaths by September 2021 were six to seven times higher than reported officially.

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

BY Alexander Muik [...] Uğur Şahin

18 Jan 2022: 678-680

Open Access

Sera from individuals vaccinated with three doses of the Pfizer/BioNtech mRNA vaccine BNT162b2 can neutralize the SARS-CoV-2 Omicron variant.

Science Translational Medicine

Volume 14| Issue 631| 9 Feb 2022

<https://www.science.org/toc/stm/current>

Research Articles

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals

BY Marie I. Samanovic, et al.

09 Feb 2022

Open Access

Prior history of COVID-19 enhances adaptive immune responses to mRNA vaccination.

Social Science & Medicine

Volume 292 January 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/292/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 12 Feb 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 45 January–February 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/45/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 2 Pages: i-iv, 121-216 February 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

EDITORS' CHOICE

Open Access

[Environmentally sustainable practices in global health research and higher education institutions: Lessons from consultation with the TropEd Global Health institutions](#)

Kate Whitfield, Alexandru Cretu, Teun Bousema, Justin Cohen

Pages: 122-128

First Published: 21 December 2021

REVIEWS

Open Access

[Are national treatment guidelines for falciparum malaria in line with WHO recommendations and is antimalarial resistance taken into consideration? – A review of guidelines in non-endemic countries](#)

Marc T. Visser, Rens Zonneveld, Thomas J. Peto, Michele van Vugt, Arjen M. Dondorp, Rob W. van der Pluijm

Pages: 129-136

First Published: 03 January 2022

[Review of authorship for COVID-19 research conducted during the 2020 first-wave epidemic in Africa reveals emergence of promising African biomedical research and persisting asymmetry of international collaborations](#)

Serge Tonen-Wolyec, Dieu-Merci Mbumba Lupaka, Salomon Batina-Agasa, François-Xavier Mbopi Keou, Laurent Bélec

Pages: 137-148

First Published: 05 January 2022

RESEARCH ARTICLES

[Epidemiology of 4963 deaths associated with COVID-19 during three pandemic waves in a Latin American city with a high mortality rate, 2020–2021](#)

Erika Viana-Cárdenas, Abel Triana, Humberto Mendoza, Emiro Buendia, Diego Viasus

Pages: 158-164
First Published: 07 December 2021

Vaccine

Volume 40, Issue 4 Pages 555-690 (28 January 2022)
<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/4>

Discussion Full text access

[Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts](#)

Franz Castro, Juan Miguel Pascale, Itzel Slocum Hewitt, Arlene Calvo
Pages 555-557

Short communication Open access

[Did the European suspension of the AstraZeneca vaccine decrease vaccine acceptance during the COVID-19 pandemic?](#)

Michael Bang Petersen, Frederik Jørgensen, Marie Fly Lindholt
Pages 558-561

Short communication Full text access

[Underserved population acceptance of combination influenza-COVID-19 booster vaccines](#)

Robert P. Lennon, Ray Block, Eric C. Schneider, Laurie Zephrein, ... Arnav Shah
Pages 562-567

Research article Open access

[Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis](#)

Anan Manomaipiboon, Uraporn Phumisantiphong, Jakravoot Maneerit, Yupin Chalearmchai, ... Thananda Trakarnvanich
Pages 587-593

Research article Open access

[Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation](#)

Samantha J. Carlson, Lara McKenzie, Leah Roberts, Christopher C. Blyth, Katie Attwell
Pages 594-600

Research article Full text access

[Levels and factors derived from the Health Action Process Approach of behavioral intentions to take up COVID-19 vaccination: A random population-based study](#)

Yanqiu Yu, Wanru Jia, Mason M.C. Lau, Joseph T.F. Lau
Pages 612-620

Research article Abstract only

[Childhood vaccination timeliness following maternal migration to an informal urban settlement in Kenya](#)

Julia M. Porth, Abram L. Wagner, Emily Treleaven, Nancy L. Fleischer, ... Matthew L. Boulton
Pages 627-639

Research article Open access

[A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines \(Cholvax vs. Shanchol\) in Dhaka, Bangladesh](#)

Fahima Chowdhury, Afroza Akter, Taufiqur Rahman Bhuiyan, Imam Tauheed, ... Firdausi Qadri

Pages 640-649

Research article Abstract only

[Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012–2016](#)

Kandace L. Amend, Bruce Turnbull, Li Zhou, Morgan A. Marks, ... John D. Seeger

Pages 682-688

Value in Health

February 2022 Volume 25 Issue 2 p161-320

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 12 Feb 2022]

Research Article metrics AWAITING PEER REVIEW

[Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns](#) [version 1; peer review: awaiting peer review]

Kurt Frey, Brittany Hagedorn, Kevin A. McCarthy, Raymond Hutubessy, Susan Annemarie Wang

Peer Reviewers Invited

Funder

Global Good Fund

PUBLISHED 09 Feb 2022

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Impact of COVID-19 pandemic and anti-pandemic measures on tuberculosis, viral hepatitis, HIV/AIDS and malaria - a systematic review](#)

Barbora Kessel, Torben Heinsohn, Jödis J Ott, Jutta Wolff, Max J Hassenstein, Berit Lange
medRxiv 2022.02.10.22270782; doi: <https://doi.org/10.1101/2022.02.10.22270782>

Fundamental limits on inferring epidemic resurgence in real time using effective reproduction numbers

Kris V Parag, Christl A. Donnelly

medRxiv 2021.09.08.21263270; doi: <https://doi.org/10.1101/2021.09.08.21263270>

SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection

Christian Gaebler, Justin DaSilva, Eva Bednarski, Frauke Muecksch, Fabian Schmidt, Yiska Weisblum, Katrina Millard, Martina Turroja, Alice Cho, Zijun Wang, Marina Caskey, Michel C. Nussenzweig, Paul Bieniasz, Theodora Hatzioannou

medRxiv 2022.02.09.22270692; doi: <https://doi.org/10.1101/2022.02.09.22270692>

Long term antibody response to SARS-CoV-2 in children

Gabor A. Dunay, Madalena Barroso, Mathias Woidy, Marta K. Danecka, Geraldine Engels, Katharina Hermann, Friederike S. Neumann, Kevin Paul, Jan Beime, Gabriele Escherich, Kristin Fehse, Lev Grinstein, Franziska Haniel, Luka J. Haupt, Laura Hecher, Torben Kehl, Christoph Kemen, Markus J. Kemper, Robin Kobbe, Aloisa Kohl, Thomas Klokow, Dominik Noerz, Jakob Olfe, Friderike Schlenker, Jessica Schmiesing, Johanna Schrum, Freya Sibbertsen, Philippe Stock, Stephan Tiede, Eik Vettorazzi, Dimitra E. Zazara, Antonia Zapf, Marc Luetgehetmann, Jun Oh, Thomas S. Mir, Ania C. Muntau, C19.CHILD Study Group, Soeren W. Gersting

medRxiv 2022.02.11.22270611; doi: <https://doi.org/10.1101/2022.02.11.22270611>

COVID-19 vaccine hesitancy in diverse groups in the UK - is the driver economic or cultural in student populations?

Francis Drobniowski, Dian Kusuma, Agnieszka Broda, Enrique Castro-Sanchez, Raheelah Ahmad

medRxiv 2021.12.14.21267773; doi: <https://doi.org/10.1101/2021.12.14.21267773>

Ethnic disparities in immunisation: analyses of zero-dose prevalence in 64 low- and middle-income countries

Bianca Oliveira Cata-Preta, Thiago Melo Santos, Andrea Wendt, Daniel R Hogan, Tewodaj Mengistu, Aluisio Jardim Dornellas Barros, Cesar Gomes Victora

medRxiv 2022.02.09.22270671; doi: <https://doi.org/10.1101/2022.02.09.22270671>

Abstract

Background The Sustainable Development Goals (SDGs) recommend stratification of health indicators by ethnic group, yet there are few studies that have assessed if there are ethnic disparities in childhood immunisation in low and middle income countries (LMICs).

Methods We identified 64 LMICs with standardized national surveys carried out since 2010, which provided information on ethnicity or a proxy variable and on vaccine coverage; 339 ethnic groups across the 64 countries were identified after excluding those with fewer than 50 children in the sample and countries with a single ethnic group. Lack of vaccination with diphtheria-pertussis-tetanus (DPT) vaccine, a proxy for no access to routine vaccination or zero-dose status, was the outcome of interest. Differences among ethnic groups were assessed using a chi-squared test for heterogeneity. Additional analyses controlled for household wealth, maternal education and urban-rural residence.

Findings The median gap between the highest and lowest zero-dose prevalence ethnic groups in all countries was equal to 10 percentage points (interquartile range 4-22; range 1 to 84) and the median ratio was 3.3 (interquartile range 1.8-6.7; range 1.1-30.4). In 35 of the 64 countries, there was

significant heterogeneity in zero-dose prevalence among the ethnic groups. In most countries, adjustment for wealth, education and residence made little difference to the ethnic gaps, but in four countries (Angola, Benin, Nigeria, and Philippines) the high-low ethnic gap decreased by over 15 pp after adjustment. Children belonging to a majority group had 29% lower prevalence of zero-dose compared to the rest of the sample.

Interpretation Statistically significant ethnic disparities in child immunisation were present in over half of the countries studied. Such inequalities have been seldom described in the published literature. Regular analyses of ethnic disparities are essential for monitoring trends, targeting resources and assessing the impact of health interventions to ensure zero-dose children are not left behind in the Sustainable Development Goals era.

How many relevant SARS-CoV-2 variants might we expect in the future?

Roberto Littera, Maurizio Melis

medRxiv 2021.11.17.21266463; doi: <https://doi.org/10.1101/2021.11.17.21266463>

Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study

Sharon Walmsley, Leah Szadkowski, Bradly Wouters, Rosemarie Clarke, Karen Colwill, Paula Rochon, Michael Brudno, Rizani Ravindran, Janet Raboud, Allison McGeer, Amit Oza, Christopher Graham, Amanda Silva, Dorin Manase, Laura Parente, Jacqueline Simpson, Roaya Monica Dayam, Adrian Pasculescu, Anne-Claude Gingras

medRxiv 2022.02.09.22270734; doi: <https://doi.org/10.1101/2022.02.09.22270734>

Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era

Alexandra Savinkina, Alyssa Bilinski, Meagan C. Fitzpatrick, A. David Paltiel, Zain Rizvi, Joshua A. Salomon, Tommy Thornhill, Gregg Gonsalves

medRxiv 2022.02.08.22270465; doi: <https://doi.org/10.1101/2022.02.08.22270465>

[See Featured Journal Articles above for detail]

A recombinant BCG-based vaccine against the human respiratory syncytial virus induces a balanced cellular immune response against viral and mycobacterial antigens

Gaspar A. Pacheco, Nicolás M. S. Gálvez, Catalina A. Andrade, Yaneisi Vázquez, Linmar Rodríguez-Guilarte, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis

medRxiv 2022.02.07.22270648; doi: <https://doi.org/10.1101/2022.02.07.22270648>

Clinical and Economic Impact of COVID-19 on Plantation Workers: Preliminary Results from the Guatemala Agricultural Workers and Respiratory Illness Impact (AGRI) Study

Daniel Olson, Diva M. Calvimontes, Molly M. Lamb, Gerber Guzman, Edgar Barrios, Andrea Chacon, Neudy Rojop, Kareen Arias, Melissa Gomez, Guillermo Antonio Bolanos, Jose Monzon, Anna N. Chard, Chelsea Iwamoto, Lindsey M. Duca, Nga Vuong, Melissa Fineman, Kelsey Lesteberg, David Beckham, Mario L. Santiago, Kendra Quicke, Gregory Ebel, Emily Zielinski Gutierrez, Eduardo Azziz-Baumgartner, Frederick G. Hayden, Hani Mansour, Kathryn Edwards, Lee S. Newman, Edwin J. Asturias

medRxiv 2022.02.07.22270274; doi: <https://doi.org/10.1101/2022.02.07.22270274>

A “step too far” or “perfect sense”? A qualitative study of British adults’ views on mandating COVID-19 vaccination and vaccine passports

Martine Stead, Allison Ford, Douglas Eadie, Hannah Biggs, Claire Elliott, Michael Ussher, Helen Bedford, Kathryn Angus, Kate Hunt, Anne Marie MacKintosh, Curtis Jessop, Andy MacGregor
medRxiv 2022.02.07.22270458; doi: <https://doi.org/10.1101/2022.02.07.22270458>

Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study

Sevda Molani, Andrew M. Baumgartner, Yeon Mi Hwang, Venkata R. Duvvuri, Jason D. Goldman, Jennifer J. Hadlock
medRxiv 2022.02.07.22270613; doi: <https://doi.org/10.1101/2022.02.07.22270613>

Effectiveness of Covid-19 Vaccines against the SARS-COV-2-Delta (B.1.617.2) in China-A Real World Study

Xinge Ma, Jianfeng Han, Hongxia Li, Chang Liu
medRxiv 2022.02.07.22270490; doi: <https://doi.org/10.1101/2022.02.07.22270490>

Wellcome Open Research [to 12 Feb 2022]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 12 Feb 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics AWAITING PEER REVIEW

Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK [version 1; peer review: awaiting peer review]

Cori Campbell, Tingyan Wang, David A. Smith, Oliver Freeman, Theresa Noble, Kinga A Várnai, Steve Harris, Hizni Salih, Gail Roadknight, Stephanie Little, Ben Glampson, Luca Mercuri, Dimitri Papadimitriou, Christopher R Jones, Vince Taylor, Afzal Chaudhry, Hang Phan, Florina Borca, Josune Olza, Frazer Warricker, Luis Romão, David Ramlakhan, Louise English, Paul Klenerman, Monique I. Andersson, Jane Collier, Eleni Nastouli, Salim I. Khakoo, William Gelson, Graham S. Cooke, Kerrie Woods, Jim Davies, Eleanor Barnes, Philippa C. Matthews

Peer Reviewers Invited

Funders

Wellcome Trust

GlaxoSmithKline

NIHR Oxford Biomedical Research Centre

PUBLISHED 11 Feb 2022

Research Article metrics AWAITING PEER REVIEW

Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study

[version 1; peer review: awaiting peer review]

Caroline Barker, Katharine Collet, Diane Gbesemete, Maria Piggan, Daniella Watson, Philippa Pristerà, Wendy Lawrence, Emma Smith, Michael Bahrami-Hessari, Halle Johnson, Katherine Baker, Ambar Qavi, Carmel McGrath, Christopher Chiu, Robert C. Read, Helen Ward

Peer Reviewers Invited

Funders

Wellcome

GCRF Networks in Vaccines Research and Development
National Institute of Health Research
PUBLISHED 10 Feb 2022

Open Letter metrics

Revised

[Towards a feminist philosophy of engagements in health-related research](#) [version 2; peer review: 2 approved]

Sonja Erikainen, Ellen Stewart, Angela Marques Filipe, Sarah Chan, Sarah Cunningham-Burley, Sophie Ilson, Gabrielle King, Carol Porteous, Stephanie Sinclair, Jamie Webb

Peer Reviewers Mary Madden; Kieran C. O'Doherty

Funder

Wellcome Trust

LATEST VERSION PUBLISHED 10 Feb 2022

Open Letter metrics AWAITING PEER REVIEW

[A network of empirical ethics teams embedded in research programmes across multiple sites: opportunities and challenges in contributing to COVID-19 research and responses](#)

[version 1; peer review: awaiting peer review]

Nothando Ngwenya, Jennifer Ilo Van Nuil, Deborah Nyirenda, Mary Chambers, Phaik Yeong Cheah, Janet Seeley, Primus Chi, Lindiwe Mafuleka, Busisiwe Nkosi, Dorcas Kamuya, Alun Davies, Mira Leonie Schneiders, Noni Mumba, Siphephelo Dlamini, Nicola Desmond, Vicki Marsh, Dinnah Rippon, Michael Parker, Sassy Molyneux

Peer Reviewers Invited

Funder

Wellcome Trust

PUBLISHED 10 Feb 2022

Abstract

Covid-19 continues to teach the global community important lessons about preparedness for research and effective action to respond to emerging health threats. We share the COVID-19 experiences of a pre-existing cross-site ethics network-the Global Health Bioethics Network-which brings together researchers and practitioners from Africa, Europe, and South east Asia. We describe the network and its members and activities, and the work-related opportunities and challenges we faced over a one-year period during the pandemic. We highlight the value of having strong and long-term empirical ethics networks embedded across diverse research institutions to be able to: 1) identify and share relevant ethics challenges and research questions and ways of 'doing research'; 2) work with key stakeholders to identify appropriate ways to contribute to the emerging health issue response – e.g. through ethics oversight, community engagement, and advisory roles at different levels; and 3) learn from each other and from diverse contexts to advocate for positive change at multiple levels. It is our view that being both embedded and long term offers particular opportunities in terms of deep institutional and contextual knowledge and relationships with and access to a wide range of stakeholders in place. Being networked offers opportunities to draw upon a wide range of expertise and perspectives operating at multiple levels, and to bring together internal and external perspectives (i.e. different positionalities). Long term funding means that the people and resources are in place and ready to respond in a timely way. However, many tensions and challenges remain, including difficulties in negotiating power and politics regarding roles that researchers and research institutions play in an emergency, and the position of empirical ethics activities in programmes of research more specifically.

We discuss some of these tensions and challenges, and consider the implications for our own and similar networks in future.

*

*

*

*

Think Tanks

Brookings

<http://www.brookings.edu/>

Accessed 12 Feb 2022

Future Development

Why global vaccine equity is the prescription for a full recovery

Indermit Gill and Michele Ruta

Friday, February 11, 2022

Testimony

Improving access to quality public education in Africa

Rebecca Winthrop

Friday, February 11, 2022

Center for Global Development [to 12 Feb 2022]

<https://www.cgdev.org/>

Accessed 12 Feb 2022

COVID-19 Vaccine Development and Rollout in Historical Perspective

Publication

February 9, 2022

This paper explores the historical record in the development and deployment of vaccines globally and puts the COVID-19 vaccine rollout in that context. Although far more can be done and should be done to speed equitable access to vaccines in the COVID-19 response, it is worth noting the revolutionary speed of both the vaccine development and the diffusion process, and the potential good news that this signals for the future of pandemic preparedness and response.

New Study: COVID-19 Vaccine Rollout Fastest in Global History

February 9, 2022

WASHINGTON—The COVID-19 vaccine rollout so far has been the fastest in global history and unprecedented in scale, according to a new study released today from the Center for Global Development, which also emphasized the considerable global inequality in access to vaccines to date. Researchers at the global think tank assessed how vaccines have been developed and deployed against 15 older infectious diseases and compared those efforts to the response to COVID-19.

The COVID-19 Vaccine Rollout Was the Fastest in Global History, but Low-Income Countries Were Left Behind

February 9, 2022

The reaction to COVID-19 has been record-breaking. Today we release a paper that reports on the development and rollout of COVID-19 vaccines in historical perspective, and it suggests a pattern of unparalleled, but still deeply inequitable, progress.

[Amanda Glassman](#), [Charles Kenny](#) and [George Yang](#)

The Vaccine Mark-Up: Counting More in ODA than We Paid for Vaccines is Illogical, Immoral, and Unpopular

February 7, 2022

Someone in a high-income country is [11x](#) more likely to have been fully inoculated than someone in a low-income country. We set out here how the OECD plans to count COVID vaccines, why this reduces the UK's overall spending on ODA, and how MPs think we should count them.

[Euan Ritchie](#), [Anthony McDonnell](#) and [Ranil Dissanayake](#)

Chatham House [to 12 Feb 2022]

<https://www.chathamhouse.org/>

Accessed 12 Feb 2022

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 12 Feb 2022

Commentary

China May Move beyond Zero-Covid. That Could Benefit Us All.

February 9, 2022 | By [J. Stephen Morrison](#), [Scott Kennedy](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 12 Feb 2022

February 10, 2022 *News Release*

Telehealth Accounted for 8% of Outpatient Visits More Than a Year into COVID-19 Pandemic, Suggesting a More Permanent Shift in How Patients Receive Care

Telehealth use skyrocketed during the early months of the pandemic. While it has since decreased somewhat from that high, it still represents a much more substantial share of health care than before COVID, a new KFF-Epic Research analysis finds. From March through August 2021, 8% of all outpatient visits were...

* * * *

Contents [click to move among sections]

::

Milestones - Perspectives

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*
*

*
*

*
*

*
*